JPH03376B2 - - Google Patents
Info
- Publication number
- JPH03376B2 JPH03376B2 JP57092251A JP9225182A JPH03376B2 JP H03376 B2 JPH03376 B2 JP H03376B2 JP 57092251 A JP57092251 A JP 57092251A JP 9225182 A JP9225182 A JP 9225182A JP H03376 B2 JPH03376 B2 JP H03376B2
- Authority
- JP
- Japan
- Prior art keywords
- mao
- formula
- acid
- compounds
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 67
- 102000010909 Monoamine Oxidase Human genes 0.000 description 57
- 108010062431 Monoamine oxidase Proteins 0.000 description 57
- 230000000694 effects Effects 0.000 description 26
- 239000003112 inhibitor Substances 0.000 description 26
- 241000700159 Rattus Species 0.000 description 21
- 210000004556 brain Anatomy 0.000 description 21
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 17
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 16
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 238000007912 intraperitoneal administration Methods 0.000 description 12
- NRNSHPCDKHOUOE-SNVBAGLBSA-N (2s)-2-amino-2-[(3,4-dihydroxyphenyl)methyl]-3-fluoropropanoic acid Chemical compound FC[C@@](N)(C(O)=O)CC1=CC=C(O)C(O)=C1 NRNSHPCDKHOUOE-SNVBAGLBSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- QPEJHSFTZVMSJH-UHFFFAOYSA-N 3-amino-5-hydroxybenzoic acid Chemical compound NC1=CC(O)=CC(C(O)=O)=C1 QPEJHSFTZVMSJH-UHFFFAOYSA-N 0.000 description 10
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 10
- 210000002569 neuron Anatomy 0.000 description 10
- -1 Park-Davis) Chemical compound 0.000 description 9
- 238000006114 decarboxylation reaction Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 229960003732 tyramine Drugs 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 235000019786 weight gain Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 150000003943 catecholamines Chemical class 0.000 description 6
- 235000013351 cheese Nutrition 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 229960004205 carbidopa Drugs 0.000 description 5
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical group C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 4
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 4
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000002427 irreversible effect Effects 0.000 description 4
- 229960001779 pargyline Drugs 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000019260 propionic acid Nutrition 0.000 description 4
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 206010038540 Renal tubular necrosis Diseases 0.000 description 3
- 239000000150 Sympathomimetic Substances 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- BTFHLQRNAMSNLC-UHFFFAOYSA-N clorgyline Chemical compound C#CCN(C)CCCOC1=CC=C(Cl)C=C1Cl BTFHLQRNAMSNLC-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229960002672 isocarboxazid Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- 229960000964 phenelzine Drugs 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001975 sympathomimetic effect Effects 0.000 description 3
- 229940064707 sympathomimetics Drugs 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960003741 tranylcypromine Drugs 0.000 description 3
- NMRNNUQAGGEBSU-UHFFFAOYSA-N 2-amino-3-(3-hydroxyphenyl)but-3-enoic acid Chemical compound OC(=O)C(N)C(=C)C1=CC=CC(O)=C1 NMRNNUQAGGEBSU-UHFFFAOYSA-N 0.000 description 2
- LAUWCWCSEOWJMQ-UHFFFAOYSA-N 2-amino-4-fluoro-3-(3-hydroxyphenyl)but-3-enoic acid Chemical compound OC(=O)C(N)C(=CF)C1=CC=CC(O)=C1 LAUWCWCSEOWJMQ-UHFFFAOYSA-N 0.000 description 2
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000013038 irreversible inhibitor Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229940117803 phenethylamine Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical class C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- FIKFCXGHULRYQK-UHFFFAOYSA-N 2-amino-3-phenylbut-3-enoic acid Chemical compound OC(=O)C(N)C(=C)C1=CC=CC=C1 FIKFCXGHULRYQK-UHFFFAOYSA-N 0.000 description 1
- STYQVTVGBBOPGX-UHFFFAOYSA-N 2-amino-4-fluoro-3-(3-hydroxy-4-methoxyphenyl)but-3-enoic acid Chemical compound COC1=CC=C(C(=CF)C(N)C(O)=O)C=C1O STYQVTVGBBOPGX-UHFFFAOYSA-N 0.000 description 1
- UMWUJXOVRWUIOX-UHFFFAOYSA-N 2-amino-4-fluoro-3-(3-hydroxy-4-methylphenyl)but-3-enoic acid Chemical compound CC1=CC=C(C(=CF)C(N)C(O)=O)C=C1O UMWUJXOVRWUIOX-UHFFFAOYSA-N 0.000 description 1
- OWCNPQKNIWRGLI-UHFFFAOYSA-N 2-phenylprop-2-en-1-amine Chemical compound NCC(=C)C1=CC=CC=C1 OWCNPQKNIWRGLI-UHFFFAOYSA-N 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000656036 Arboa Species 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 206010061297 Mucosal erosion Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- BKPRVQDIOGQWTG-ICOOEGOYSA-N [(1s,2r)-2-phenylcyclopropyl]azanium;[(1r,2s)-2-phenylcyclopropyl]azanium;sulfate Chemical compound [O-]S([O-])(=O)=O.[NH3+][C@H]1C[C@@H]1C1=CC=CC=C1.[NH3+][C@@H]1C[C@H]1C1=CC=CC=C1 BKPRVQDIOGQWTG-ICOOEGOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000003973 alkyl amines Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Chemical group 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Chemical group 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- HBGGXOJOCNVPFY-UHFFFAOYSA-N diisononyl phthalate Chemical group CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C HBGGXOJOCNVPFY-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 doseâresponse relationship Toxicity 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000231 kidney cortex Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940110127 marplan Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229940087524 nardil Drugs 0.000 description 1
- 238000010910 nasogastric intubation Methods 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940087824 parnate Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002315 pressor effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
ãç£æ¥äžã®å©çšåéã
æ¬çºæã¯è¬ç掻æ§ããæ°èŠååç©ããããã®å
åç©ã®è£œé æ³ããããã®ååç©ãå«ãã§ãã補è¬
çµæç©ã«é¢ããã ã¢ãã¢ãã³ãªãã·ããŒãŒé»å®³å€ïŒMAOé»å®³
å€ïŒãšããŠç¥ãããŠããçš®é¡ã®ååç©ã¯æãã€ç
ã®æ²»çã«20幎以äžã粟ç¥å»åŠã§äœ¿çšãããŠãã
ãã°ãããã³åã³ã®ã«ãã³ã®ã¶ ãã¢ãŒãã³ããž
ã«ã« ããŒã·ã¹ ãªã ã»ã©ããŠãŒãã€ãã¯ã¹ç¬¬
ïŒç·šãã¯ãã©ã³ ãããªãã·ã³ã° ã«ã³ãããŒã€
ã³ã³ãŒãã¬ãŒããããããŠãŒãšãŒã¯ã1980ã427
ã430é åç §ããæãã€ç ã®æ²»çã«ç±³åœã§æšä»äœ¿çš
ãããŠããMAOé»å®³å€ã¯ãã©ãã«ã·ãããã³
ïŒPARNATEïŒSKFïŒãããšãã«ãžã³
ïŒNARDILïŒParkâDavisïŒåã³ã€ãœã«ã«ãããµ
ãžãïŒMARPLANïŒRocheïŒã§ãããæŽã«å¥ã®
MAOé»å®³å€ãã«ã®ãªã³ïŒEUTRON AbbottïŒ
ãé«è¡å§ã®æ²»çã«å ¥æåºæ¥ãããã€ãžã· ã€ã³ãº
ãã¹ã¯ ãããšã³ã¹ã34ç·šãã¡ãã€ã«ã« ãšã³
ãããã¯ã¹ ã³ãŒãã¬ãŒã·ãšã³ããªã©ãã«ãããŠ
ãŒãžã€ãŒãžãŒã1980ã1327ã1328é ïŒããšãã«ãž
ã³ïŒã1466ã1468é ïŒã€ãœã«ã«ãããµãžãïŒã1628
ã1630é ïŒãã©ãã«ã·ãããã³ïŒãåã³521ã522
é ïŒãã«ã®ãªã³ïŒãåç §ããMAOé»å®³å€ã¯ææ
çã®äžå®ç¶æ ãªã©ã®ä»ã®ç²Ÿç¥å»åŠçé害ãæ²»çã
ãã®ã«ã䜿çšåºæ¥ãã MAOé»å®³å€ã¯ãæãã€ç ãªã©ã®ç²Ÿç¥å»åŠã軜
æžããããã«ã¯ãäžæ¢ç¥çµäžã®ïŒåã¯ãã以äžã®
çç©æŽ»åã«ããã¢ãã¢ãã³ã®æ¿åºŠãå¢å ãããã
ãšã«ãã€ãŠäœçšãããã¢ãã¢ãã³ãªãã·ããŒãŒé µ
çŽ ïŒMAOïŒã¯é žåçãã¢ãããŒã·ãšã³ãéããŠ
ã¢ãã¢ãã³ã®çç©å解ã觊åªããã®ã§ã¢ãã¢ãã³
ã®ä»£è¬ç調æŽã«æŒããŠéèŠãªåœ¹å²ããããMAO
ãé»å®³ããããšã«ãã€ãŠã¢ãã¢ãã³ã®å解ã¯å°ã
ãããã®çµæã¢ãã¢ãã³ã®ççæ©èœãžã®å©çšãå¢
倧ãããMAOã®æ¢ç¥ã®åºè³ªã§ããçç掻æ§ã¢ã
ã¢ãã³ã®ãªãã«ã¯(a)ã«ãã³ãŒã«ã¢ãã³ïŒäŸãã°ã
ããã³ããšããããªã³ãåã³ãã«ãšããããªã³ïŒ
åã³ã€ã³ããŒã«ã¢ãã³ïŒäŸãã°ããªãã¿ãã³åã³
ïŒâããããã·ããªãã¿ãã³ïŒãªã©ã®æè¬ãããŠ
ãŒããã©ã³ã¹ããã¿ãŒïŒç¥çµäŒéç©è³ªïŒãã¢ãã¢
ãã³é¡ã(b)æè¬ããã¬ãŒã¹ãã¢ãã³é¡ïŒäŸãã°ïœ
âãã©ãã³ãããšããã«ã¢ãã³ããã¬ââã¡ã
ã«ãã¹ã¿ãã³ïŒåã³(c)ãã©ãã³ãããã ãçºæã解決ããããšãã課é¡ã æãã€ç æ²»çã§ã®MAOé»å®³å€ã®æçšæ§ã¯ãã
ãã®è©Šè¬ã®æäžãæãé£ç©åºè³ªåã¯è¬å€ã®è¬çäœ
çšã匷ãããã®ã§å±éºãªããšãã«ã¯å°æ»çãªåœ±é¿
ã«ã€ãªããåŸãããã«éããããã®ã§ãã€ããäŸ
ãã°MAOé»å®³å€ãåãã人ã¯ãMAOé»å®³å€ã
æ¶å管åã³èèäžã®ãã©ãã³ã®ä»£è¬å解ãå°ãã
é«ããã©ãã³åŸªç°æ°Žæºããã®çµæãšããŠã®æ«æ¢¢ã§
ã®ã«ãã³ãŒã«ã¢ãã³ã®æŸåºãåã³æçµçãªã²ã©ã
é«è¡å§ãçããããã«ãé«ãã©ãã³å«éãæãã
é£ç©ïŒããŒãºãªã©ïŒã®æåããããã°ãªããªãã
ããŒãºæåããèµ·ãããã©ãã³ã®è¡å§äžæå¹æã®
MAOé»å®³å€ã«ããçžä¹åã³ããã«ããçããé«
è¡å§äºäŸã¯äžè¬ã«ãããŒãºåå¿ãåã¯ãããŒãºå¹
æããšããŠç¥ãããŠããããã®ãããæ £çšã®
MAOçæ³ãè¡ã€ãŠãã人ã¯ããèªèº«MAOã®åº
質ã§ããçŽæ¥äœçšãã亀æç¥çµè奮å€ïŒåã¯ãã®
åé§äœïŒïŒäŸãã°ãããã³ããšããããªã³ããã«
ãšããããªã³ãåã¯ïŒ¬âããŒãïŒåã³éæ¥çã«äœ¿
çšãã亀æç¥çµè奮å€ïŒäŸãã°ã¢ã³ããšã¿ãã³å
ã¯è¡ç®¡åçž®å€ãå«ãã§ããè¬å±ã§å£²ãããããã
æ¯èç±ãåã¯äœé調æŽçšèª¿å€ïŒãäžããããããš
ã¯åºæ¥ãªããéæ¥çã«äœçšãã亀æç¥çµè奮è¬ã®
æå§å¹æã匷ããããšã¯ç¹ã«æ·±é ãªãã®ã§ããã
ããã¯ãã®æ§ãªè¬å€ãäž»ãšããŠç¥çµçµæ«ã«ã«ãã³
ãŒã«ã¢ãã³ãæŸåºããããšã«ãã€ãŠæ«æ¢¢çã«äœçš
ããéé¢ãããã«ãã³ãŒã«ã¢ãã³ã®æ¿åºŠãMAO
ãçµãã«ãã³ãŒã«ã¢ãã³ã®ä»£è¬å解ããããå°ã
ããããªãã°å±éºãªãŸã§ã«äžæããããã§ããã
æŽã«ç¹å®ã®MAOé»å®³å€ã¯ä»ã®MAOé»å®³å€ãå
ã¯éå§å€ããžãã³ã¶ãã³ãææãã€å€ãã¡ããªãž
ã³ãCNSæå¶å€ãåã³æã³ãªã³äœåå€ãšçµåã
ãŠäœ¿çšãããã¹ãã§ã¯ãªãã çååŠçåã³è¬çåŠçç 究ã¯MAOé µçŽ ã
ãMAO åãïŒMAOâïŒåã³ãMAO åã
ïŒMAOâïŒãšããŠç¥ãããïŒã€ã®åœ¢ã§ååšã
ãããšã瀺ããŠããããããã®åœ¢ã¯äœã®åšå®äžã§
ã®ååžã«æŒãŠããããã®åºè³ªç¹ç°æ§ã«æŒãŠãåã³
é»å®³å€ã«å¯Ÿããæåæ§ã«æŒãŠçžéãããäžè¬ã«
MAOâã¯éžææ§ã«ãããããããŠãŒããã©ã³
ã¹ããã¿ãŒïŒç¥çµäŒéç©è³ªïŒãã®ã¢ãã¢ãã³ïŒãš
ããããªã³ããã«ãšããããªã³ãåã³ïŒâããã
ãã·ããªãã¿ãã³ïŒãé žåããäžæ¹ãMAOâ
ã¯ããã¬ãŒã¹ãã¢ãã¢ãã³ïŒïœâããªãã¿ãã³ã
ããšããã«ã¢ãã³ãåã³ãã¬ââã¡ãã«ãã¹ã¿
ãã³ïŒãé žåãããMAOâãMAOâãã
ã©ãã³ãããªãã¿ãã³ãåã³ãããã³ãé žåã
ããããã人ã§ã¯ãããã³ã奜ãŸããMAOâ
ã«å¯Ÿããåºè³ªã§ããããšã瀺ãããŠãããããã
ã®åœ¢ã¯ãŸãé»å®³å€ã«å¯Ÿããæåæ§ã§ãç°ãªã€ãŠã
ããåŸã€ãŠé»å®³å€ã®ååŠæ§é åã³ïŒåã¯é»å®³å€ãš
é µçŽ ã®çžå¯Ÿçæ¿åºŠã«äŸåããŠåªå çã«é»å®³ãåã
åŸããæãã€ã®æ²»çã«ç±³åœã§çŸåšå£²ãããŠãã
MAOé»å®³å€ã¯ïŒãã©ãã«ã·ãããã³ãããšãã«
ãžã³ãåã³ã€ãœã«ã«ãããµãžãïŒMAOã«å¯Ÿãã
äœçšã«æŒãŠåªå çã§ã¯ãªãããããçš®ã ã®ååç©
ãMAOã®åªå çé»å®³å€ãšããŠåœæè¡ã§ç¥ãããŠ
ããŠãæãéèŠãªã®ã¯ã¯ãã«ã®ãªã³ããã«ã®ãª
ã³ãåã³ïŒ¬âããã¬ãã«ã§ãã€ãŠããããã¯ãã¹
ãŠèšåºçã«æå¹ãªææãã€å€ã§ããããšãå ±åã
ããŠãããMAOâã¯ã¯ãã«ã®ãªã³ã«ãã€ãŠåª
å çã«é»å®³ããããMAOâã¯ãã«ã®ãªã³åã³
âããã¬ãã«ã«ãã€ãŠåªå çã«é»å®³ãåããã
MAOé»å®³å€ã®ãéžææ§ãã¯é»å®³å€ãé µçŽ ã®äžæ¹
ã®åœ¢ã«å¯ŸããŠãã倧ããªèŠªåæ§ãæããããçã
ãã®ã§ãããåŸã€ãŠMAOâåã¯MAOâã«
察ããçäœå ã§ã®MAOé»å®³å€ã®éžææ§ã¯æäžé
ã«äŸåããæäžéãå¢ããšéžææ§ã¯å€±ããããã¯
ãã«ã®ãªã³ããã«ã®ãªã³ãåã³ïŒ¬âããã¬ãã«ã¯
äœæäžéã§éžæçé»å®³å€ã§ãããããããé«æäž
éã§ã¯éžæçã§ãªããMAOâåã³MAOâ
åã³ãã®éžæçé»å®³ã«é¢ããæç®ã¯éåžžã«å€ã
ãäŸãã°ã°ãããã³åã³ã®ã«ãã³ãåæžã204ã
205é ïŒããçãã©ã€ããµã€ãšã³ã¹14ã2061
ïŒ1974ïŒïŒããŒãã€ãŒããã€ãªã±ãã«ã« ãã¢ãŒã
ã³ããžãŒã27ã1889ïŒ1978ïŒïŒã¯ããŒã«ã10ç« ã
151ã171é åã³ãµã³ãã©ãŒã11ç« 173ã181é ãè¬
ãšããŠã®é µçŽ é»å®³å€äžããšã ãµã³ãã©ãŒç·šãã
ã¯ãã©ã³ ãã¬ã¹ ãªããããããã³ãã³1980ïŒ
ãªãããŒçããµã€ã³ ãã¢ãŒãã³ããžãŒ62ã123
ïŒ1979ïŒïŒãã³çãã©ã€ããµã€ãšã³ã¹26ã877
ïŒ1980ïŒïŒåã³ã¢ãã¢ãã³ãªãã·ããŒãŒïŒã¹ãã©ã¯
ãã€ãŒ ãã¢ã³ã¯ã·ãšã³ ã¢ã³ã ã¢ã«ã¿ãŒã
ãã¢ã³ã¯ã·ãšã³ã«ããçš®ã ã®èšäºããã€ãŒ ã·ã³
ã¬ãŒçç·šãã¢ã«ãããã¯ãã¬ã¹ãããŠãŒãšãŒã¯
1979ãåç §ãã MAOã®éžæçé»å®³å€ã®ãã¡ãâããã¬ãã«
ã¯MAOâã®åªå é»å®³ãèµ·ããäœæäžéã§ãã
ãŒãºå¹æãã芳ãããªãã®ã§èå³ãæãããã
ãã¯ããŒã« ãã€ã³ãº111ã113é 1979幎ïŒæåç §ã
ãã®èŠ³å¯ã¯è žã®ç²èãäž»ã«MAOâãå«æãã
ããã¯é»å®³ãããªãããã«æåããããã©ãã³ã®
é žååã³é€å»ãå¯èœã«ããã®ã§äºæãããªãããš
ã§ã¯ãªããâããã¬ãã«ã®MAOâã«å¯Ÿãã
éžææ§ã¯ãæå§å€ã®ã«ãã³ãŒã«ã¢ãã³ã®çžä¹ã®ã
ãã®é«è¡å§ã®æ§ãªæ«æ¢¢ã®å¯äœçšãçããããšãªã
ã«ããŒãã³ãœã³ç ã®æ²»çã®ããã«ïŒ¬âããã匷ã
ãèœåãããããšã®çç±ã§ããåŸãããªãŒçã©ã³
ã»ãã791ã795é ã1977幎10æ15æ¥åã³ãã«ã¯ã
ã€ã€ãŒ ã©ã³ã»ããã439ã443é ã1977幎ïŒæ26
æ¥ãã ã課é¡ã解決æ段ã ååç©ãããªãã ãåŒäžR1ã¯
åç©ã®è£œé æ³ããããã®ååç©ãå«ãã§ãã補è¬
çµæç©ã«é¢ããã ã¢ãã¢ãã³ãªãã·ããŒãŒé»å®³å€ïŒMAOé»å®³
å€ïŒãšããŠç¥ãããŠããçš®é¡ã®ååç©ã¯æãã€ç
ã®æ²»çã«20幎以äžã粟ç¥å»åŠã§äœ¿çšãããŠãã
ãã°ãããã³åã³ã®ã«ãã³ã®ã¶ ãã¢ãŒãã³ããž
ã«ã« ããŒã·ã¹ ãªã ã»ã©ããŠãŒãã€ãã¯ã¹ç¬¬
ïŒç·šãã¯ãã©ã³ ãããªãã·ã³ã° ã«ã³ãããŒã€
ã³ã³ãŒãã¬ãŒããããããŠãŒãšãŒã¯ã1980ã427
ã430é åç §ããæãã€ç ã®æ²»çã«ç±³åœã§æšä»äœ¿çš
ãããŠããMAOé»å®³å€ã¯ãã©ãã«ã·ãããã³
ïŒPARNATEïŒSKFïŒãããšãã«ãžã³
ïŒNARDILïŒParkâDavisïŒåã³ã€ãœã«ã«ãããµ
ãžãïŒMARPLANïŒRocheïŒã§ãããæŽã«å¥ã®
MAOé»å®³å€ãã«ã®ãªã³ïŒEUTRON AbbottïŒ
ãé«è¡å§ã®æ²»çã«å ¥æåºæ¥ãããã€ãžã· ã€ã³ãº
ãã¹ã¯ ãããšã³ã¹ã34ç·šãã¡ãã€ã«ã« ãšã³
ãããã¯ã¹ ã³ãŒãã¬ãŒã·ãšã³ããªã©ãã«ãããŠ
ãŒãžã€ãŒãžãŒã1980ã1327ã1328é ïŒããšãã«ãž
ã³ïŒã1466ã1468é ïŒã€ãœã«ã«ãããµãžãïŒã1628
ã1630é ïŒãã©ãã«ã·ãããã³ïŒãåã³521ã522
é ïŒãã«ã®ãªã³ïŒãåç §ããMAOé»å®³å€ã¯ææ
çã®äžå®ç¶æ ãªã©ã®ä»ã®ç²Ÿç¥å»åŠçé害ãæ²»çã
ãã®ã«ã䜿çšåºæ¥ãã MAOé»å®³å€ã¯ãæãã€ç ãªã©ã®ç²Ÿç¥å»åŠã軜
æžããããã«ã¯ãäžæ¢ç¥çµäžã®ïŒåã¯ãã以äžã®
çç©æŽ»åã«ããã¢ãã¢ãã³ã®æ¿åºŠãå¢å ãããã
ãšã«ãã€ãŠäœçšãããã¢ãã¢ãã³ãªãã·ããŒãŒé µ
çŽ ïŒMAOïŒã¯é žåçãã¢ãããŒã·ãšã³ãéããŠ
ã¢ãã¢ãã³ã®çç©å解ã觊åªããã®ã§ã¢ãã¢ãã³
ã®ä»£è¬ç調æŽã«æŒããŠéèŠãªåœ¹å²ããããMAO
ãé»å®³ããããšã«ãã€ãŠã¢ãã¢ãã³ã®å解ã¯å°ã
ãããã®çµæã¢ãã¢ãã³ã®ççæ©èœãžã®å©çšãå¢
倧ãããMAOã®æ¢ç¥ã®åºè³ªã§ããçç掻æ§ã¢ã
ã¢ãã³ã®ãªãã«ã¯(a)ã«ãã³ãŒã«ã¢ãã³ïŒäŸãã°ã
ããã³ããšããããªã³ãåã³ãã«ãšããããªã³ïŒ
åã³ã€ã³ããŒã«ã¢ãã³ïŒäŸãã°ããªãã¿ãã³åã³
ïŒâããããã·ããªãã¿ãã³ïŒãªã©ã®æè¬ãããŠ
ãŒããã©ã³ã¹ããã¿ãŒïŒç¥çµäŒéç©è³ªïŒãã¢ãã¢
ãã³é¡ã(b)æè¬ããã¬ãŒã¹ãã¢ãã³é¡ïŒäŸãã°ïœ
âãã©ãã³ãããšããã«ã¢ãã³ããã¬ââã¡ã
ã«ãã¹ã¿ãã³ïŒåã³(c)ãã©ãã³ãããã ãçºæã解決ããããšãã課é¡ã æãã€ç æ²»çã§ã®MAOé»å®³å€ã®æçšæ§ã¯ãã
ãã®è©Šè¬ã®æäžãæãé£ç©åºè³ªåã¯è¬å€ã®è¬çäœ
çšã匷ãããã®ã§å±éºãªããšãã«ã¯å°æ»çãªåœ±é¿
ã«ã€ãªããåŸãããã«éããããã®ã§ãã€ããäŸ
ãã°MAOé»å®³å€ãåãã人ã¯ãMAOé»å®³å€ã
æ¶å管åã³èèäžã®ãã©ãã³ã®ä»£è¬å解ãå°ãã
é«ããã©ãã³åŸªç°æ°Žæºããã®çµæãšããŠã®æ«æ¢¢ã§
ã®ã«ãã³ãŒã«ã¢ãã³ã®æŸåºãåã³æçµçãªã²ã©ã
é«è¡å§ãçããããã«ãé«ãã©ãã³å«éãæãã
é£ç©ïŒããŒãºãªã©ïŒã®æåããããã°ãªããªãã
ããŒãºæåããèµ·ãããã©ãã³ã®è¡å§äžæå¹æã®
MAOé»å®³å€ã«ããçžä¹åã³ããã«ããçããé«
è¡å§äºäŸã¯äžè¬ã«ãããŒãºåå¿ãåã¯ãããŒãºå¹
æããšããŠç¥ãããŠããããã®ãããæ £çšã®
MAOçæ³ãè¡ã€ãŠãã人ã¯ããèªèº«MAOã®åº
質ã§ããçŽæ¥äœçšãã亀æç¥çµè奮å€ïŒåã¯ãã®
åé§äœïŒïŒäŸãã°ãããã³ããšããããªã³ããã«
ãšããããªã³ãåã¯ïŒ¬âããŒãïŒåã³éæ¥çã«äœ¿
çšãã亀æç¥çµè奮å€ïŒäŸãã°ã¢ã³ããšã¿ãã³å
ã¯è¡ç®¡åçž®å€ãå«ãã§ããè¬å±ã§å£²ãããããã
æ¯èç±ãåã¯äœé調æŽçšèª¿å€ïŒãäžããããããš
ã¯åºæ¥ãªããéæ¥çã«äœçšãã亀æç¥çµè奮è¬ã®
æå§å¹æã匷ããããšã¯ç¹ã«æ·±é ãªãã®ã§ããã
ããã¯ãã®æ§ãªè¬å€ãäž»ãšããŠç¥çµçµæ«ã«ã«ãã³
ãŒã«ã¢ãã³ãæŸåºããããšã«ãã€ãŠæ«æ¢¢çã«äœçš
ããéé¢ãããã«ãã³ãŒã«ã¢ãã³ã®æ¿åºŠãMAO
ãçµãã«ãã³ãŒã«ã¢ãã³ã®ä»£è¬å解ããããå°ã
ããããªãã°å±éºãªãŸã§ã«äžæããããã§ããã
æŽã«ç¹å®ã®MAOé»å®³å€ã¯ä»ã®MAOé»å®³å€ãå
ã¯éå§å€ããžãã³ã¶ãã³ãææãã€å€ãã¡ããªãž
ã³ãCNSæå¶å€ãåã³æã³ãªã³äœåå€ãšçµåã
ãŠäœ¿çšãããã¹ãã§ã¯ãªãã çååŠçåã³è¬çåŠçç 究ã¯MAOé µçŽ ã
ãMAO åãïŒMAOâïŒåã³ãMAO åã
ïŒMAOâïŒãšããŠç¥ãããïŒã€ã®åœ¢ã§ååšã
ãããšã瀺ããŠããããããã®åœ¢ã¯äœã®åšå®äžã§
ã®ååžã«æŒãŠããããã®åºè³ªç¹ç°æ§ã«æŒãŠãåã³
é»å®³å€ã«å¯Ÿããæåæ§ã«æŒãŠçžéãããäžè¬ã«
MAOâã¯éžææ§ã«ãããããããŠãŒããã©ã³
ã¹ããã¿ãŒïŒç¥çµäŒéç©è³ªïŒãã®ã¢ãã¢ãã³ïŒãš
ããããªã³ããã«ãšããããªã³ãåã³ïŒâããã
ãã·ããªãã¿ãã³ïŒãé žåããäžæ¹ãMAOâ
ã¯ããã¬ãŒã¹ãã¢ãã¢ãã³ïŒïœâããªãã¿ãã³ã
ããšããã«ã¢ãã³ãåã³ãã¬ââã¡ãã«ãã¹ã¿
ãã³ïŒãé žåãããMAOâãMAOâãã
ã©ãã³ãããªãã¿ãã³ãåã³ãããã³ãé žåã
ããããã人ã§ã¯ãããã³ã奜ãŸããMAOâ
ã«å¯Ÿããåºè³ªã§ããããšã瀺ãããŠãããããã
ã®åœ¢ã¯ãŸãé»å®³å€ã«å¯Ÿããæåæ§ã§ãç°ãªã€ãŠã
ããåŸã€ãŠé»å®³å€ã®ååŠæ§é åã³ïŒåã¯é»å®³å€ãš
é µçŽ ã®çžå¯Ÿçæ¿åºŠã«äŸåããŠåªå çã«é»å®³ãåã
åŸããæãã€ã®æ²»çã«ç±³åœã§çŸåšå£²ãããŠãã
MAOé»å®³å€ã¯ïŒãã©ãã«ã·ãããã³ãããšãã«
ãžã³ãåã³ã€ãœã«ã«ãããµãžãïŒMAOã«å¯Ÿãã
äœçšã«æŒãŠåªå çã§ã¯ãªãããããçš®ã ã®ååç©
ãMAOã®åªå çé»å®³å€ãšããŠåœæè¡ã§ç¥ãããŠ
ããŠãæãéèŠãªã®ã¯ã¯ãã«ã®ãªã³ããã«ã®ãª
ã³ãåã³ïŒ¬âããã¬ãã«ã§ãã€ãŠããããã¯ãã¹
ãŠèšåºçã«æå¹ãªææãã€å€ã§ããããšãå ±åã
ããŠãããMAOâã¯ã¯ãã«ã®ãªã³ã«ãã€ãŠåª
å çã«é»å®³ããããMAOâã¯ãã«ã®ãªã³åã³
âããã¬ãã«ã«ãã€ãŠåªå çã«é»å®³ãåããã
MAOé»å®³å€ã®ãéžææ§ãã¯é»å®³å€ãé µçŽ ã®äžæ¹
ã®åœ¢ã«å¯ŸããŠãã倧ããªèŠªåæ§ãæããããçã
ãã®ã§ãããåŸã€ãŠMAOâåã¯MAOâã«
察ããçäœå ã§ã®MAOé»å®³å€ã®éžææ§ã¯æäžé
ã«äŸåããæäžéãå¢ããšéžææ§ã¯å€±ããããã¯
ãã«ã®ãªã³ããã«ã®ãªã³ãåã³ïŒ¬âããã¬ãã«ã¯
äœæäžéã§éžæçé»å®³å€ã§ãããããããé«æäž
éã§ã¯éžæçã§ãªããMAOâåã³MAOâ
åã³ãã®éžæçé»å®³ã«é¢ããæç®ã¯éåžžã«å€ã
ãäŸãã°ã°ãããã³åã³ã®ã«ãã³ãåæžã204ã
205é ïŒããçãã©ã€ããµã€ãšã³ã¹14ã2061
ïŒ1974ïŒïŒããŒãã€ãŒããã€ãªã±ãã«ã« ãã¢ãŒã
ã³ããžãŒã27ã1889ïŒ1978ïŒïŒã¯ããŒã«ã10ç« ã
151ã171é åã³ãµã³ãã©ãŒã11ç« 173ã181é ãè¬
ãšããŠã®é µçŽ é»å®³å€äžããšã ãµã³ãã©ãŒç·šãã
ã¯ãã©ã³ ãã¬ã¹ ãªããããããã³ãã³1980ïŒ
ãªãããŒçããµã€ã³ ãã¢ãŒãã³ããžãŒ62ã123
ïŒ1979ïŒïŒãã³çãã©ã€ããµã€ãšã³ã¹26ã877
ïŒ1980ïŒïŒåã³ã¢ãã¢ãã³ãªãã·ããŒãŒïŒã¹ãã©ã¯
ãã€ãŒ ãã¢ã³ã¯ã·ãšã³ ã¢ã³ã ã¢ã«ã¿ãŒã
ãã¢ã³ã¯ã·ãšã³ã«ããçš®ã ã®èšäºããã€ãŒ ã·ã³
ã¬ãŒçç·šãã¢ã«ãããã¯ãã¬ã¹ãããŠãŒãšãŒã¯
1979ãåç §ãã MAOã®éžæçé»å®³å€ã®ãã¡ãâããã¬ãã«
ã¯MAOâã®åªå é»å®³ãèµ·ããäœæäžéã§ãã
ãŒãºå¹æãã芳ãããªãã®ã§èå³ãæãããã
ãã¯ããŒã« ãã€ã³ãº111ã113é 1979幎ïŒæåç §ã
ãã®èŠ³å¯ã¯è žã®ç²èãäž»ã«MAOâãå«æãã
ããã¯é»å®³ãããªãããã«æåããããã©ãã³ã®
é žååã³é€å»ãå¯èœã«ããã®ã§äºæãããªãããš
ã§ã¯ãªããâããã¬ãã«ã®MAOâã«å¯Ÿãã
éžææ§ã¯ãæå§å€ã®ã«ãã³ãŒã«ã¢ãã³ã®çžä¹ã®ã
ãã®é«è¡å§ã®æ§ãªæ«æ¢¢ã®å¯äœçšãçããããšãªã
ã«ããŒãã³ãœã³ç ã®æ²»çã®ããã«ïŒ¬âããã匷ã
ãèœåãããããšã®çç±ã§ããåŸãããªãŒçã©ã³
ã»ãã791ã795é ã1977幎10æ15æ¥åã³ãã«ã¯ã
ã€ã€ãŒ ã©ã³ã»ããã439ã443é ã1977幎ïŒæ26
æ¥ãã ã課é¡ã解決æ段ã ååç©ãããªãã ãåŒäžR1ã¯
ãåŒãã§ããã
R3ã¯æ°ŽçŽ åã¯äœçŽã¢ã«ã³ãã·ã§ãããã
åŒã®ååç©ã®é©åœãªç¡æ¯æ§ã®è£œè¬åŠçã«åã
å ¥ããããå¡©ã¯åœæè¡ã§ç¥ãããŠãããαâã¢ã
ãåºã®ãããã³åã«ãã圢æãããé žä»å å¡©åã³
ã«ã«ãã³é žåºã®äžåã«ãã€ãŠåœ¢æãããå¡©ãå«
ããä»»æã®ã¢ããé žã®æ§ã«ãååç©ã¯äž¡æ§ã€ãªã³
圢ã§ååšããããšãåºæ¥ããé žä»å å¡©ã®äŸã¯æ¬¡ã®
é žãã圢æããããã®ã§ãããå¡©é žãèåæ°ŽçŽ
é žãã¹ã«ãã³é žãç¡«é žãçé žãç¡é žããã¬ã€ã³
é žãããã«é žãå®æ¯éŠé žãã¢ã¹ã³ã«ãã³é žããã¢
ã€ãã¯ã¢ã·ããããã¯ãé žãã¡ã¿ã³ã¹ã«ãã³é žã
é ¢é žãããããªã³é žãé ç³é žãã¯ãšã³é žãä¹³é žã
ãªã³ãŽé žããã³ãã«é žãã±ã€ç®é žããã«ããã³
é žãã€ã¿ã³ã³é žãåã³ãã³ãŒã³ã¹ã«ãã³é žãã«ã«
ãã³é žã®äžåã«ãã€ãŠåœ¢æãããå¡©ã®äŸã¯éå±å¡©
ïŒäŸãã°ãããªãŠã ãã«ãªãŠã ããªããŠã ãã«ã«
ã·ãŠã ãåã¯ãã°ãã·ãŠã ïŒåã³ã¢ã³ã¢ããŠã å
ã¯çœ®æã¢ã³ã¢ããŠã å¡©ã§ãããã«ãªãŠã åã³ãã
ãªãŠã å¡©ã奜ãŸããã ååç©ã®å¥œãŸããé¡ã®ãã®ã¯ (i) R1ãïŒâããããã·ããšãã«ã§ããåŒã®
ååç©ã§ããã æ¬çºæã®ååç©ã®å¥œãŸããå ·äœäŸã¯ ïŒâã¢ããâïŒâãã«ãªãâïŒâïŒ3â²âããã
ãã·ããšãã«ïŒâïŒâããã³é žã ïŒâã¢ããâïŒâãã«ãªãâïŒâïŒ3â²ãããã
ã·â4â²âã¡ãã«ããšãã«ïŒâïŒâããã³é ž ã§ããã åŒã®ååç©ã¯MAOã®éå¯éçé»å®³å€ã§ãã
æãç©è³ªã®çäœå åé§äœïŒåã¯ãããã©ãã°ïŒã§
ãããäžèšååç©ã¯æãã€çã®æ²»çã®ããã«ç²Ÿç¥
å»åŠã«æŒãŠæçšã§ãããåŒã®ååç©ã¯è©Šéšç®¡å
ïŒã€ã³ãããïŒã§MAOã®éå¯éçé»å®³å€ã§ã¯ãª
ããçäœå ã§MAOã®éå¯éçé»å®³ãã€ããåº
ãããããŠãããã®ææãã€å¹æãçºæ®ãããã
ã«ã¯åŒã®ååç©ã¯ãäžã«ããããåŒãåã¯
ã§ç€ºãããïŒâããšãã«ã¢ãªã«ã¢ãã³ã§ãã掻
æ§ä»£è¬ç©ã«å€æãããªããŠã¯ãªããªãã ïŒR1ã¯
å ¥ããããå¡©ã¯åœæè¡ã§ç¥ãããŠãããαâã¢ã
ãåºã®ãããã³åã«ãã圢æãããé žä»å å¡©åã³
ã«ã«ãã³é žåºã®äžåã«ãã€ãŠåœ¢æãããå¡©ãå«
ããä»»æã®ã¢ããé žã®æ§ã«ãååç©ã¯äž¡æ§ã€ãªã³
圢ã§ååšããããšãåºæ¥ããé žä»å å¡©ã®äŸã¯æ¬¡ã®
é žãã圢æããããã®ã§ãããå¡©é žãèåæ°ŽçŽ
é žãã¹ã«ãã³é žãç¡«é žãçé žãç¡é žããã¬ã€ã³
é žãããã«é žãå®æ¯éŠé žãã¢ã¹ã³ã«ãã³é žããã¢
ã€ãã¯ã¢ã·ããããã¯ãé žãã¡ã¿ã³ã¹ã«ãã³é žã
é ¢é žãããããªã³é žãé ç³é žãã¯ãšã³é žãä¹³é žã
ãªã³ãŽé žããã³ãã«é žãã±ã€ç®é žããã«ããã³
é žãã€ã¿ã³ã³é žãåã³ãã³ãŒã³ã¹ã«ãã³é žãã«ã«
ãã³é žã®äžåã«ãã€ãŠåœ¢æãããå¡©ã®äŸã¯éå±å¡©
ïŒäŸãã°ãããªãŠã ãã«ãªãŠã ããªããŠã ãã«ã«
ã·ãŠã ãåã¯ãã°ãã·ãŠã ïŒåã³ã¢ã³ã¢ããŠã å
ã¯çœ®æã¢ã³ã¢ããŠã å¡©ã§ãããã«ãªãŠã åã³ãã
ãªãŠã å¡©ã奜ãŸããã ååç©ã®å¥œãŸããé¡ã®ãã®ã¯ (i) R1ãïŒâããããã·ããšãã«ã§ããåŒã®
ååç©ã§ããã æ¬çºæã®ååç©ã®å¥œãŸããå ·äœäŸã¯ ïŒâã¢ããâïŒâãã«ãªãâïŒâïŒ3â²âããã
ãã·ããšãã«ïŒâïŒâããã³é žã ïŒâã¢ããâïŒâãã«ãªãâïŒâïŒ3â²ãããã
ã·â4â²âã¡ãã«ããšãã«ïŒâïŒâããã³é ž ã§ããã åŒã®ååç©ã¯MAOã®éå¯éçé»å®³å€ã§ãã
æãç©è³ªã®çäœå åé§äœïŒåã¯ãããã©ãã°ïŒã§
ãããäžèšååç©ã¯æãã€çã®æ²»çã®ããã«ç²Ÿç¥
å»åŠã«æŒãŠæçšã§ãããåŒã®ååç©ã¯è©Šéšç®¡å
ïŒã€ã³ãããïŒã§MAOã®éå¯éçé»å®³å€ã§ã¯ãª
ããçäœå ã§MAOã®éå¯éçé»å®³ãã€ããåº
ãããããŠãããã®ææãã€å¹æãçºæ®ãããã
ã«ã¯åŒã®ååç©ã¯ãäžã«ããããåŒãåã¯
ã§ç€ºãããïŒâããšãã«ã¢ãªã«ã¢ãã³ã§ãã掻
æ§ä»£è¬ç©ã«å€æãããªããŠã¯ãªããªãã ïŒR1ã¯
ãåŒãã§ãããR3ã¯æ°ŽçŽ åã¯äœçŽã¢ã«
ã³ãã·ã§ããïŒã
åŒã®ååç©ã®åŒã®æŽ»æ§ä»£è¬ç©ãžã®çäœå
å€
æã¯è³éŠæâã¢ããé žãã«ã«ããã·ã©ãŒãŒ
ïŒAADCïŒãšããŠç¥ãããŠããé µçŽ ã§è§Šåªããã
ãã«ã«ããã·ã¬ãŒã·ãšã³åå¿ãéããŠèµ·ããã
AADCã¯çš®ã ã®çç©åŠçã«éèŠãªã¢ããé žïŒäŸ
ãã°ããŒããããã·ã³ãããšãã«ã¢ã©ãã³ãããª
ãããã¢ã³åã³ïŒâããããã·ããªãããã¢ã³ïŒ
ãè±ã«ã«ããã·ã«åããŠå¯Ÿå¿ããã¢ãã¢ãã³é¡ã
çæããããšãç¥ãããŠããã åŒã®çäœå åã³ã€ã³ãããã®MAOé»å®³å€ã§
ããææãã€ååç©ã¯1981幎ïŒæïŒæ¥åºé¡ã®çªå·
第268555ã®ããŒïŒãã€ã®ãã¢ãªã«ã¢ãã³MAOé»
害å€ããšããå称ã®ä¿å±äžã®ç±³åœåºé¡ã«èšèŒãã
ç¹èš±è«æ±ãããŠããã AADCã¯è³åã³è³å€çµç¹ã®äž¡æ¹ã«ååšããã
ãšãç¥ãããŠãããåŸã€ãŠåŒã®ååç©ã®ãã«ã«
ããã·ã¬ãŒã·ãšã³ã¯è³åã³è³å€çµç¹ã®äž¡æ¹ã§è¡ãª
ããåŸããã®çµæMAOã®é»å®³ã䌎ããåŒã®å
åç©ãè³å€ã®AADCãåªå çã«å°ããããšã®åº
æ¥ãååç©ãšçµåããŠæäžããããšã«ãã€ãŠã掻
æ§ä»£è¬ç©ãçç£ãããã«ã«ããã¬ãŒã·ãšã³åå¿ã
äž»ãšããŠè³äžã§è¡ãããåŸã€ãŠäž»ãšããŠè³ã®
MAOãé»å®³ããããåŸã€ãŠæãã€ç æ²»çã®ãã
ã«æ«æ¢¢AADCé»å®³å€ãšçµåããŠåŒã®ååç©ã
æäžãããšå®è³ªçã«ãããŒãºå¹æãåã³æ £çšã®
MAOé»å®³å€çæ³ã«æ®éé¢é£ããŠåºãŠããä»ã®æ«
梢ç䜵çºçãé¿ããå©ç¹ããããããããè³å€
AADCé»å®³å€ãšçµåããŠåŒã®ååç©ã¯MAOã®
äœçœ®æ什ïŒsite directedïŒé»å®³ãäžããé»å®³ã¯é«
ãAADC掻æ§ãæããè³ã«äž»ãšããŠéå®ãããŠ
ããã åŒã®ååç©ãšçµåããŠäœ¿çšããããã®é©åœãª
AADCé»å®³å€ã¯åœæ¥è ã«ã¯æããã§ããã競äº
çåã³éå¯éçé»å®³å€ã®äž¡æ¹ã䜿çšãåŸãã䜿çš
æäžéã§AADCé»å®³å€ã¯è³äžã®AADCãå®è³ªç
ã«é»å®³ããããšãªãè³å€ã§AADCãé»å®³ããã
ãšãåºæ¥ãªããŠã¯ãªããªããåŒã®ååç©ãšçµå
ããŠäœ¿çšããããã®AADCé»å®³å€ã®äŸã¯ã«ã«ã
ããåã³ãã³ãŒã©ãžãã§ããããããã®ååç©ã¯
ããŒãã³ãœã³çå矀ã®æ²»çã®ããæäžãããå€å
æ§ïŒ¬âããŒãã®æ«æ¢¢ã§ã®è±ã«ã«ããã·ã«åãå°ã
ãã®ã«æçšã§ããããšãããã€ãŠããã第21ç« ç¹
ã«482ã483é ã㶠ãã¢ãŒãã³ããžã«ã« ããŒã·
ã¹ ãªã ã»ã©ããŠãŒãã€ãã¯ã¹ãã°ãããã³å
ã³ã®ã«ãã³ç·šããã¯ãã©ã³ ãããªãã·ã³ã° ã«
ã³ãã㌠ã€ã³ã³ãŒãã¬ãŒããããããŠãŒãšãŒ
ã¯ãïŒç·šã1980åç §ããé©åœãªAADCé»å®³å€ã®ä»
ã®äŸã¯ïŒâã¢ããâïŒâïŒã¢ããã«ãªãã¡ãã«å
ã¯ãžãã«ãªãã¡ãã«ïŒâïŒâïŒã¢ãããããã·ããš
ãã«åã¯ãžããããã·ããšãã«ïŒããããªã³é žå
ã³é¡äŒŒã®ååç©ã§ãã€ãŠããããã¯1980幎11æ26
æ¥åºé¡ã®ç¬¬ïŒïŒ210500çªãããŒïŒãã€åã³ãšã ïŒ
ãŠã³ã°ã®å称ãαâããã¡ãã«ã¢ããé žãã®ä¿å±
äžã®ç±³åœåºé¡ã«èšèŒããç¹èš±è«æ±ãããŠãããäž
èšã®ïŒâããã¡ãã«åïŒâã¢ããâïŒâïŒçœ®æã
ãšãã«ïŒâããããªã³é žããã«ã®ãŒç¹èš±ç¬¬868881
åã³882105ã«èšèŒãããŠããã奜ãŸããååç©ã¯
ïŒâã¢ããâïŒâïŒã¢ããã«ãªãã¡ãã«åã¯ãžã
ã«ãªãã¡ãã«ïŒâïŒâïŒ3â²ïŒ4â²âãžããããã·ããš
ãã«ïŒããããªã³é žåã³ãã®2â²ïŒ3â²âåã¯2â²ïŒ
5â²âãžãããã·ããšãã«ç°æ§äœã§ããã ããããïŒâã¢ããâïŒâããšãã«âïŒâãã
ã³é žãïŒâã¢ããâïŒâïŒ3â²âããããã·ããšã
ã«ïŒâïŒâããã³é žãã®ã¡ãã«ïŒâããšãã«âïŒ
âããããšãŒãåã³ã¡ãã«ïŒâïŒ3â²âããã©ãã
ããã©ãããã·ããšãã«ïŒâïŒâããããšãŒãã
ãã®è£œé ã¯ã¢ãŒã« ãã¢ãªïŒR.ChariïŒã«ãã€ãŠ
ãã·ã³ã»ã·ã¹ ãªãβïŒÎ³âã¢ã³ãµããŠã¬ãŒãã
ã ã¢ãã ã¢ã·ãã ã¢ãº ããã³ã·ã€ã« ã€
ã¬ããŒã·ãã« ãšã³ã¶ã€ã ã€ã³ããã¿ãŒãºããš
ããé¡ã®å士è«æã1979幎ãŠãããŒã·ãã€ãŒãªã
ãããã€ãäžã«èšèŒãããŠããïŒå°å·ç©ããã·
ã¬ã³å·ã¢ã³ ã¢ã«ãã¢ããŠãããŒã·ãã€ãŒ ãã€
ã¯ããã€ã«ã ã€ã³ã¿ãã·ãšãã«ããå ¥æåºæ¥
ãïŒã åŒã®ååç©ã¯äžèšã®ããèªèº«ç¥ãããæ¹æ³ã§
補é åºæ¥ãã äžã®åå¿åŒã§Rcã¯åŒ
æã¯è³éŠæâã¢ããé žãã«ã«ããã·ã©ãŒãŒ
ïŒAADCïŒãšããŠç¥ãããŠããé µçŽ ã§è§Šåªããã
ãã«ã«ããã·ã¬ãŒã·ãšã³åå¿ãéããŠèµ·ããã
AADCã¯çš®ã ã®çç©åŠçã«éèŠãªã¢ããé žïŒäŸ
ãã°ããŒããããã·ã³ãããšãã«ã¢ã©ãã³ãããª
ãããã¢ã³åã³ïŒâããããã·ããªãããã¢ã³ïŒ
ãè±ã«ã«ããã·ã«åããŠå¯Ÿå¿ããã¢ãã¢ãã³é¡ã
çæããããšãç¥ãããŠããã åŒã®çäœå åã³ã€ã³ãããã®MAOé»å®³å€ã§
ããææãã€ååç©ã¯1981幎ïŒæïŒæ¥åºé¡ã®çªå·
第268555ã®ããŒïŒãã€ã®ãã¢ãªã«ã¢ãã³MAOé»
害å€ããšããå称ã®ä¿å±äžã®ç±³åœåºé¡ã«èšèŒãã
ç¹èš±è«æ±ãããŠããã AADCã¯è³åã³è³å€çµç¹ã®äž¡æ¹ã«ååšããã
ãšãç¥ãããŠãããåŸã€ãŠåŒã®ååç©ã®ãã«ã«
ããã·ã¬ãŒã·ãšã³ã¯è³åã³è³å€çµç¹ã®äž¡æ¹ã§è¡ãª
ããåŸããã®çµæMAOã®é»å®³ã䌎ããåŒã®å
åç©ãè³å€ã®AADCãåªå çã«å°ããããšã®åº
æ¥ãååç©ãšçµåããŠæäžããããšã«ãã€ãŠã掻
æ§ä»£è¬ç©ãçç£ãããã«ã«ããã¬ãŒã·ãšã³åå¿ã
äž»ãšããŠè³äžã§è¡ãããåŸã€ãŠäž»ãšããŠè³ã®
MAOãé»å®³ããããåŸã€ãŠæãã€ç æ²»çã®ãã
ã«æ«æ¢¢AADCé»å®³å€ãšçµåããŠåŒã®ååç©ã
æäžãããšå®è³ªçã«ãããŒãºå¹æãåã³æ £çšã®
MAOé»å®³å€çæ³ã«æ®éé¢é£ããŠåºãŠããä»ã®æ«
梢ç䜵çºçãé¿ããå©ç¹ããããããããè³å€
AADCé»å®³å€ãšçµåããŠåŒã®ååç©ã¯MAOã®
äœçœ®æ什ïŒsite directedïŒé»å®³ãäžããé»å®³ã¯é«
ãAADC掻æ§ãæããè³ã«äž»ãšããŠéå®ãããŠ
ããã åŒã®ååç©ãšçµåããŠäœ¿çšããããã®é©åœãª
AADCé»å®³å€ã¯åœæ¥è ã«ã¯æããã§ããã競äº
çåã³éå¯éçé»å®³å€ã®äž¡æ¹ã䜿çšãåŸãã䜿çš
æäžéã§AADCé»å®³å€ã¯è³äžã®AADCãå®è³ªç
ã«é»å®³ããããšãªãè³å€ã§AADCãé»å®³ããã
ãšãåºæ¥ãªããŠã¯ãªããªããåŒã®ååç©ãšçµå
ããŠäœ¿çšããããã®AADCé»å®³å€ã®äŸã¯ã«ã«ã
ããåã³ãã³ãŒã©ãžãã§ããããããã®ååç©ã¯
ããŒãã³ãœã³çå矀ã®æ²»çã®ããæäžãããå€å
æ§ïŒ¬âããŒãã®æ«æ¢¢ã§ã®è±ã«ã«ããã·ã«åãå°ã
ãã®ã«æçšã§ããããšãããã€ãŠããã第21ç« ç¹
ã«482ã483é ã㶠ãã¢ãŒãã³ããžã«ã« ããŒã·
ã¹ ãªã ã»ã©ããŠãŒãã€ãã¯ã¹ãã°ãããã³å
ã³ã®ã«ãã³ç·šããã¯ãã©ã³ ãããªãã·ã³ã° ã«
ã³ãã㌠ã€ã³ã³ãŒãã¬ãŒããããããŠãŒãšãŒ
ã¯ãïŒç·šã1980åç §ããé©åœãªAADCé»å®³å€ã®ä»
ã®äŸã¯ïŒâã¢ããâïŒâïŒã¢ããã«ãªãã¡ãã«å
ã¯ãžãã«ãªãã¡ãã«ïŒâïŒâïŒã¢ãããããã·ããš
ãã«åã¯ãžããããã·ããšãã«ïŒããããªã³é žå
ã³é¡äŒŒã®ååç©ã§ãã€ãŠããããã¯1980幎11æ26
æ¥åºé¡ã®ç¬¬ïŒïŒ210500çªãããŒïŒãã€åã³ãšã ïŒ
ãŠã³ã°ã®å称ãαâããã¡ãã«ã¢ããé žãã®ä¿å±
äžã®ç±³åœåºé¡ã«èšèŒããç¹èš±è«æ±ãããŠãããäž
èšã®ïŒâããã¡ãã«åïŒâã¢ããâïŒâïŒçœ®æã
ãšãã«ïŒâããããªã³é žããã«ã®ãŒç¹èš±ç¬¬868881
åã³882105ã«èšèŒãããŠããã奜ãŸããååç©ã¯
ïŒâã¢ããâïŒâïŒã¢ããã«ãªãã¡ãã«åã¯ãžã
ã«ãªãã¡ãã«ïŒâïŒâïŒ3â²ïŒ4â²âãžããããã·ããš
ãã«ïŒããããªã³é žåã³ãã®2â²ïŒ3â²âåã¯2â²ïŒ
5â²âãžãããã·ããšãã«ç°æ§äœã§ããã ããããïŒâã¢ããâïŒâããšãã«âïŒâãã
ã³é žãïŒâã¢ããâïŒâïŒ3â²âããããã·ããšã
ã«ïŒâïŒâããã³é žãã®ã¡ãã«ïŒâããšãã«âïŒ
âããããšãŒãåã³ã¡ãã«ïŒâïŒ3â²âããã©ãã
ããã©ãããã·ããšãã«ïŒâïŒâããããšãŒãã
ãã®è£œé ã¯ã¢ãŒã« ãã¢ãªïŒR.ChariïŒã«ãã€ãŠ
ãã·ã³ã»ã·ã¹ ãªãβïŒÎ³âã¢ã³ãµããŠã¬ãŒãã
ã ã¢ãã ã¢ã·ãã ã¢ãº ããã³ã·ã€ã« ã€
ã¬ããŒã·ãã« ãšã³ã¶ã€ã ã€ã³ããã¿ãŒãºããš
ããé¡ã®å士è«æã1979幎ãŠãããŒã·ãã€ãŒãªã
ãããã€ãäžã«èšèŒãããŠããïŒå°å·ç©ããã·
ã¬ã³å·ã¢ã³ ã¢ã«ãã¢ããŠãããŒã·ãã€ãŒ ãã€
ã¯ããã€ã«ã ã€ã³ã¿ãã·ãšãã«ããå ¥æåºæ¥
ãïŒã åŒã®ååç©ã¯äžèšã®ããèªèº«ç¥ãããæ¹æ³ã§
補é åºæ¥ãã äžã®åå¿åŒã§Rcã¯åŒ
ãåŒãåã¯
ãåŒã
ã®åºã§ãããåã¯åŒã§Raã«ããå®çŸ©ãããåº
ã§ãããRbã¯ïŒC1âC4ïŒã¢ã«ãã«ã§ãããB1ã¯
第ïŒçŽã¢ããåºã®ä¿è·åºã§ãããã¯ããçŽ ãå¡©
çŽ åã¯èçŽ ã§ãããRcåã¯Raã§å®çŸ©ãããä¿è·
åº(B)ãããã©ããããã©ãã«ã§ããåŸãªãããšã
æ¡ä»¶ãšããã段éã§åŒXIã®ã¢ã«ãã«ïŒâããâ
ïŒâããããšãŒãååç©ã¯ããèªèº«ã¯ç¥ãããæ¹
æ³ã§ã奜ãŸããã¯ïŒâã§åå¡©åççŽ äžã§èçŽ åã
ãåŒXIIã®ã¢ã«ãã«ïŒïŒïŒâãžããã¢âïŒâããã
ãããšãŒãååç©ãäžããã段éã§åŒXIIã®åå
ç©ã¯ããèªèº«ã¯ç¥ãããæ¹æ³ã§ã奜ãŸããã¯éæµ
枩床ã§ããã©ããããã©ã³ïŒTHFïŒäžã§æ°ŽçŽ å
ãããªãŠã åŠçã«ãã€ãŠãè±ããã²ã³åæ°ŽçŽ ãè¡
ã€ãŠåŒã®ã¢ã«ãã«ïŒâããâïŒâããã¢âïŒ
âããããšãŒãååç©ãäžãããããããèªèº«ã¯
ç¥ãããæ¹æ³ã§ã奜ãŸããã¯â78âã§THFäžã§
ãªããŠã ãžã€ãœãããã«ã¢ããåŠçã§åŒã®å¯Ÿ
å¿ããïŒâããããšãŒãååç©ã«ç°æ§åããã
ïŒæ®µéïŒã段éã§åŒã®ïŒâããããšãŒãå
åç©ã¯ã¢ã³ã¢ãã¢ã§å¥œãŸããã¯ãžã¡ãã«ã¹ã«ãã
ã·ãïŒDMSOïŒäžã§ç°å¢æž©åºŠã§åŠçãããŠåŒ
ã®ã¢ã«ãã«âïŒâããâïŒâã¢ããâïŒâãã
ããšãŒãååç©ãäžããããã¯æ®µéã§ããèªèº«
ç¥ãããæ¹æ³ã§åŠçãããŠåŒã®ïŒ®âä¿è·èªå°
äœãçæãããåŒã®ïŒ®âä¿è·èªå°äœã®åŒã®
æçµçæç©ãžã®å€æïŒæ®µéïŒã¯ïŒæ®µéæ¹æ³ã§é
æåºæ¥ãããã㯠(a) ç°å¢æž©åºŠã§ã®ã¢ã«ã«ãªå æ°Žå解ïŒå¥œãŸããã¯
ãžãªããµã³ïŒæ°Žäžã®æ°Žé žåãªããŠã ã«ããïŒã§
ãšã¹ãã«ã¢ã«ãã«åºïŒRbïŒãé€ãããšã (b) ãã®ããã«çæããå¡©ãäžåïŒçŽPH4.0ã奜
ãŸããã¯åžå¡©é žã«ããïŒããŠå¯Ÿå¿ããéé¢é žã
äžããããšã (c) æž©åãªæ¡ä»¶ïŒïŒã25âã®æž©åºŠïŒäžã§é žïŒå¥œãŸ
ããã¯åžå¡©é žåã¯ãšãŒãã«æ§å¡©åæ°ŽçŽ ïŒã§16æ
éãŸã§åŠçããŠè³éŠæOHä¿è·åº(B)åã³Î±âã¢
ããåºïŒB1ïŒãé€ãããšãããªãã RbãåŒã§ç¬¬ïŒããã«ã®ãšãã¯æ®µé(a)åã³
(b)ã¯é€ãåŸãã åŒã®ååç©ã§OHåºãããšãã«ç°ã®ïŒäœã«å
åšãOHåã¯ã¢ã«ã³ãã·ãããšãã«ç°ã®ïŒïŒïŒäœ
ã«ãªããã®ã補é ããããšãã¯ãæŽã«å€æŽããæ
é ã䜿çšåºæ¥ãããã®æé ã¯åŒã®ååç©è£œé ã«
äžã«èšããæé ãšäŒŒãŠãããããã åºçºç©è³ªã¯
Raã§å®çŸ©ãããè³éŠæOHä¿è·åº(B)ãïŒC1âC4ïŒ
çŽéã¢ã«ãã«åºã§ãããåŸãåŒXIã®ååç©ã§ã
ãããã®è£œé ã¯äžã®æ®µéïŒïŒ¢ïŒïŒ£ïŒïŒ€åã³ïŒ¥ã«
èšèŒã®ãã®ã«äŒŒãæ¹æ³ã§è¡ãªãããããããã段
éã§çæãããâä¿è·èªå°äœã¯éæµæž©åºŠã§ã®
47ïŒ ã®èåæ°ŽçŽ é žã§ã®åŠçã«ãã€ãŠäžæ®µéã§åŒ
ã®ååç©ã«å€æåºæ¥ãããã®æ§ãªåŠçã¯è³éŠæâ
OHä¿è·åº(B)ãé€ãããšã¹ãã«ã¢ã«ãã«åºïŒRbïŒ
ãé€ããαâã¢ããä¿è·åºïŒB1ïŒãé€ããå¥ã®
æ¹æ³ãšããŠãâä¿è·èªå°äœã¯åžå¡©é žåã¯é£œåãš
ãŒãã«æ§å¡©åæ°ŽçŽ ã§åŠçããŠÎ±âã¢ããä¿è·åºã
é€ãããããã47ïŒ èåæ°ŽçŽ ã§åŠçããããšãåº
æ¥ãã 段éã§å¥œãŸããâä¿è·åºã¯ããžâ第ïŒãã
ã«ãžã«ãŒãããŒããšã®åå¿ãªã©ã®ããèªäœã¯æ¢ç¥
ã®æ¹æ³ã§åŒã®ååç©ã«å°å ¥åºæ¥ã第ïŒçŽãã
ãã·ã«ã«ããã«ïŒBocïŒã§ããã åŒã®ååç©ã¯åºçºç©è³ªãšããŠåŒã®ååç©
ã䜿çšããŠåŒã®ååç©è£œé ã«èšãããšåæ§ã®æ¹
æ³ã§è£œé åºæ¥ãã åŒäžRbãRcåã³ã¯åŒXIã«é¢ããŠäžã«å®çŸ©ã
ãæå³ãæããã åŒãXIåã¯ã®åºçºç©è³ªã¯ åŒ
ã§ãããRbã¯ïŒC1âC4ïŒã¢ã«ãã«ã§ãããB1ã¯
第ïŒçŽã¢ããåºã®ä¿è·åºã§ãããã¯ããçŽ ãå¡©
çŽ åã¯èçŽ ã§ãããRcåã¯Raã§å®çŸ©ãããä¿è·
åº(B)ãããã©ããããã©ãã«ã§ããåŸãªãããšã
æ¡ä»¶ãšããã段éã§åŒXIã®ã¢ã«ãã«ïŒâããâ
ïŒâããããšãŒãååç©ã¯ããèªèº«ã¯ç¥ãããæ¹
æ³ã§ã奜ãŸããã¯ïŒâã§åå¡©åççŽ äžã§èçŽ åã
ãåŒXIIã®ã¢ã«ãã«ïŒïŒïŒâãžããã¢âïŒâããã
ãããšãŒãååç©ãäžããã段éã§åŒXIIã®åå
ç©ã¯ããèªèº«ã¯ç¥ãããæ¹æ³ã§ã奜ãŸããã¯éæµ
枩床ã§ããã©ããããã©ã³ïŒTHFïŒäžã§æ°ŽçŽ å
ãããªãŠã åŠçã«ãã€ãŠãè±ããã²ã³åæ°ŽçŽ ãè¡
ã€ãŠåŒã®ã¢ã«ãã«ïŒâããâïŒâããã¢âïŒ
âããããšãŒãååç©ãäžãããããããèªèº«ã¯
ç¥ãããæ¹æ³ã§ã奜ãŸããã¯â78âã§THFäžã§
ãªããŠã ãžã€ãœãããã«ã¢ããåŠçã§åŒã®å¯Ÿ
å¿ããïŒâããããšãŒãååç©ã«ç°æ§åããã
ïŒæ®µéïŒã段éã§åŒã®ïŒâããããšãŒãå
åç©ã¯ã¢ã³ã¢ãã¢ã§å¥œãŸããã¯ãžã¡ãã«ã¹ã«ãã
ã·ãïŒDMSOïŒäžã§ç°å¢æž©åºŠã§åŠçãããŠåŒ
ã®ã¢ã«ãã«âïŒâããâïŒâã¢ããâïŒâãã
ããšãŒãååç©ãäžããããã¯æ®µéã§ããèªèº«
ç¥ãããæ¹æ³ã§åŠçãããŠåŒã®ïŒ®âä¿è·èªå°
äœãçæãããåŒã®ïŒ®âä¿è·èªå°äœã®åŒã®
æçµçæç©ãžã®å€æïŒæ®µéïŒã¯ïŒæ®µéæ¹æ³ã§é
æåºæ¥ãããã㯠(a) ç°å¢æž©åºŠã§ã®ã¢ã«ã«ãªå æ°Žå解ïŒå¥œãŸããã¯
ãžãªããµã³ïŒæ°Žäžã®æ°Žé žåãªããŠã ã«ããïŒã§
ãšã¹ãã«ã¢ã«ãã«åºïŒRbïŒãé€ãããšã (b) ãã®ããã«çæããå¡©ãäžåïŒçŽPH4.0ã奜
ãŸããã¯åžå¡©é žã«ããïŒããŠå¯Ÿå¿ããéé¢é žã
äžããããšã (c) æž©åãªæ¡ä»¶ïŒïŒã25âã®æž©åºŠïŒäžã§é žïŒå¥œãŸ
ããã¯åžå¡©é žåã¯ãšãŒãã«æ§å¡©åæ°ŽçŽ ïŒã§16æ
éãŸã§åŠçããŠè³éŠæOHä¿è·åº(B)åã³Î±âã¢
ããåºïŒB1ïŒãé€ãããšãããªãã RbãåŒã§ç¬¬ïŒããã«ã®ãšãã¯æ®µé(a)åã³
(b)ã¯é€ãåŸãã åŒã®ååç©ã§OHåºãããšãã«ç°ã®ïŒäœã«å
åšãOHåã¯ã¢ã«ã³ãã·ãããšãã«ç°ã®ïŒïŒïŒäœ
ã«ãªããã®ã補é ããããšãã¯ãæŽã«å€æŽããæ
é ã䜿çšåºæ¥ãããã®æé ã¯åŒã®ååç©è£œé ã«
äžã«èšããæé ãšäŒŒãŠãããããã åºçºç©è³ªã¯
Raã§å®çŸ©ãããè³éŠæOHä¿è·åº(B)ãïŒC1âC4ïŒ
çŽéã¢ã«ãã«åºã§ãããåŸãåŒXIã®ååç©ã§ã
ãããã®è£œé ã¯äžã®æ®µéïŒïŒ¢ïŒïŒ£ïŒïŒ€åã³ïŒ¥ã«
èšèŒã®ãã®ã«äŒŒãæ¹æ³ã§è¡ãªãããããããã段
éã§çæãããâä¿è·èªå°äœã¯éæµæž©åºŠã§ã®
47ïŒ ã®èåæ°ŽçŽ é žã§ã®åŠçã«ãã€ãŠäžæ®µéã§åŒ
ã®ååç©ã«å€æåºæ¥ãããã®æ§ãªåŠçã¯è³éŠæâ
OHä¿è·åº(B)ãé€ãããšã¹ãã«ã¢ã«ãã«åºïŒRbïŒ
ãé€ããαâã¢ããä¿è·åºïŒB1ïŒãé€ããå¥ã®
æ¹æ³ãšããŠãâä¿è·èªå°äœã¯åžå¡©é žåã¯é£œåãš
ãŒãã«æ§å¡©åæ°ŽçŽ ã§åŠçããŠÎ±âã¢ããä¿è·åºã
é€ãããããã47ïŒ èåæ°ŽçŽ ã§åŠçããããšãåº
æ¥ãã 段éã§å¥œãŸããâä¿è·åºã¯ããžâ第ïŒãã
ã«ãžã«ãŒãããŒããšã®åå¿ãªã©ã®ããèªäœã¯æ¢ç¥
ã®æ¹æ³ã§åŒã®ååç©ã«å°å ¥åºæ¥ã第ïŒçŽãã
ãã·ã«ã«ããã«ïŒBocïŒã§ããã åŒã®ååç©ã¯åºçºç©è³ªãšããŠåŒã®ååç©
ã䜿çšããŠåŒã®ååç©è£œé ã«èšãããšåæ§ã®æ¹
æ³ã§è£œé åºæ¥ãã åŒäžRbãRcåã³ã¯åŒXIã«é¢ããŠäžã«å®çŸ©ã
ãæå³ãæããã åŒãXIåã¯ã®åºçºç©è³ªã¯ åŒ
ãåŒãåã¯
ãåŒã
ã®ã±ãã³ãé©åœãªããªã¢ã«ãã«ãã¹ããã¢ã»ããŒ
ãã§ããžã¡ããã·ãšã¿ã³ïŒDMEïŒäžã§ïŒâã§æ°Ž
çŽ åãããªãŠã ã®ååšäžã«åŠçããããšã«ãã€ãŠ
ãŠã€ããããåå¿ã«ããç¥ãããæ¹æ³ã§è£œé åºæ¥
ããåŒãåã¯ã®ã±ãã³ã¯æ¢ç¥ååç©
ã§ãããåã¯æ¢ç¥ååç©ããåœæè¡ã§ç¥ãããæ¹
æ³ã«ãã€ãŠåã¯ãã®èªæã®å€æ³ã«ãã€ãŠè£œé åºæ¥
ããäŸãã°åŒã®ååç©ã¯æ¢ç¥æ¹æ³ã§ããã²ã³
åãããŠåŒïŒžåã¯ã®ååç©ã補é ãããå
ã¯é©åœã«çœ®æããããã³ãŒã³ååç©ã¯ããªãŒãã«
ã¯ã©ããåå¿ã䜿çšããŠã¢ã·ã«ååºæ¥ãã åœæ¥è ã«èªèãããããã«ãåŒã®ååç©ã¯è³
éŠæOHåºåã³ã¢ã«ãã¢ãŒNH2åºãæããããã
ã®äžæ¹åã¯äž¡æ¹ã¯ããèªäœç¥ãããæ¹æ³ã§ã¢ã·ã«
ååºæ¥ããåœæè¡ã§ã¢ã«ã«ã³é žåã¯å€©ç¶ã®ã¢ãã
é žããèªå°ãããâã¢ã·ã«åã¯ïŒ¯âã¢ã·ã«åºã
é€ããéé¢âNH2åºåã¯OHåºãçäœå ã§çãã
ããšãç¥ãããŠãããåŸã€ãŠã¢ã·ã«èªå°äœãæ¬çº
æã®ç®çã«äœ¿çšåºæ¥ãããäœãã¢ã·ã«åºã¯çäœå
ã§é€ããæãŸããã¢ããé žãäžããããšãæ¡ä»¶ãš
ãããæãçš®ã®ä»ã®èªå°äœãçäœå ã§å€æãããŠ
éé¢è³éŠæããããã·åã¯Î±âã¢ããåºãçºçã
ãããšãèªèãããããã®æ§ãªèªå°äœã®äŸã¯ïŒâ
ã¢ããâïŒâãããªãâïŒâïŒ3â²ïŒ4â²âã¡ãã¬ã³
ãžãªãã·ããšãã«ïŒâïŒâããã³é žã§ããããŸã
ãšã¹ãã«åã³å¡©ä»¥å€ã®ã«ã«ãã³é žå®èœåºã®æãèª
å°äœãæ¬çºæã®ç®çã«äœ¿çšåºæ¥ãããšãæçœã§ã
ãããã®äŸã¯ç¬¬ïŒçŽã¢ãã³ã第ïŒçŽåã¯ç¬¬ïŒçŽã¢
ã«ãã«ã¢ãã³åã³å€©ç¶ã¢ãã³é žã®Î±åã¯æ«ç«¯
NH2åºã«ãã€ãŠåœ¢æãããã¢ããã§ããããªã
ãªãã°ã¢ããçµåã¯çäœå ã§éè£ãããããšãç¥
ãããŠããããã§ããã åŒã®ååç©ã¯äžæççŽ ååãæãããããšã
ã³ããªããŒãå¯èœã§ãããæ¬çºæã®ååç©ã¯çç©
掻æ§ãšãã³ããªããŒåã¯ã©ã»ãäœã®åœ¢ã§ãã€ãŠã
ãã åŒã®ååç©ã¯æãã©ã»ãçæç©ãåå²ããã
ãšã«ãã€ãŠãåã¯ã©ã»ãäœåºçºç©è³ªãåã¯åæã®
ä»»æã®éœåãã段éã§äžéäœãåå²ããããšã«ã
ã€ãŠçŽç²ãªãšãã³ããªããŒåœ¢ã§åŸããããåå²å®
æœæ³ã¯ååŠã§åšç¥ã§ãããæ¬æ现æžã§æäžç¯å²ã
äžããããããããã¯ã©ã»ãäœã«ãé©çšåºæ¥ãã æŽã«åŒã®ååç©ã¯ïŒŠã§è¡šãããã眮æåºã
R1ã§è¡šããããåºã«å¯Ÿãã·ã¹åã¯ãã©ã³ã¹ã®ã
ãããã®åœ¢ã§ååšåºæ¥ããæ¬çºæã®ååç©ãçŽç²
ãªã·ã¹åã¯ãã©ã³ã¹åœ¢ã§åã¯ãããã®æ··åç©ãšã
ãŠååšãåŸãããšãç解ãããã æãã€çãæ²»çããã®ã«äœ¿çšããæã¯ãåŒã®
ååç©ã®æå¹ãªæäžéã¯äœ¿çšãããåã ã®åå
ç©ãæãã€çã®ã²ã©ããšè³ªãåã³æ²»çãããåã
ã®æ£è ã«ãã€ãŠå€ãã§ããããäžè¬ã«åŒã®åå
ç©ã§æå¹ãªçµæã¯äžæ¥ã«ã€ãçŽ0.5ããçŽ50mgã®
é©éæ°Žæºã§çµå£åã¯éçµå£çã«éæãããã æ²»çæ³ã¯æ¯èŒçäœãé©éã§éå§ãããã¹ãã§ã
ã®åŸé©éã¯ææã®å¹æãéæãããè¿å¢å ãã
ãã AADCé»å®³å€ãæãã€çã®æ²»çã«åŒã®åå
ç©ãšäžç·ã«æäžãããæãAADCé»å®³å€ã®æå¹
æäžéã¯è³äžã§AADC觊åªè±ã«ã«ããã·ã«åã
å®è³ªäžé®æããã«è³å€ã§äžèšååç©ã®AADC觊
åªè±ã«ã«ããã·ã«åãå®è³ªçã«é®æã§ããªããã°
ãªããªããæå¹ãªæäžéã¯ãããããªããã䜿çš
ãããåã ã®ååç©åã³æäžãããææãã€å€ã
ããã©ã°ïŒProdrugïŒã®æäžéã«ãã€ãŠå€ããã§
ããããäžè¬ã«ã«ã«ãããŒããšãããŒã©ãžããã§
ã¯æå¹ãªçµæã¯äžæ¥ã«ä»ãçŽ50ä¹è³500mgã®æäž
éæ°Žæºã§å¥œãŸããã¯çŽ50ä¹è³250mgã®æäžéæ°Žæº
ã§çµå£åã¯éçµå£çã«éæããããäžèšïŒâãã
ã¡ãã«åãããïŒâã¢ããâïŒâïŒçœ®æããšãã«ïŒ
ããããªã³é žã§ã¯ãæå¹ãªçµæã¯äžæ¥ã«ã€ãçŽ
0.1mgä¹è³1000mgã®æäžéæ°Žæºã§çµå£åã¯éçµå£
çã«éæãããã AADCé»å®³å€ã¯åŒã®ååç©ã®æäžãšå®è³ªäž
åæã«ãåã¯ãã®å ã«äžç·ã«æäžãããããåã«
æäžãããæãAADCé»å®³å€ã¯æäžã®çµè·¯ãšæ²»
çãããŠããçç¶ã®ã²ã©ãã«ãã€ãŠå ç«ã€ããšïŒ
æéè¿ã®éã«äžããããããšãã§ããã AADCé»å®³å€ãšçµã¿åãããŠäœ¿çšããããšã
ã¯ãåŒã®ååç©ãšAADCé»å®³å€ã¯ãååç©å
ã¯AADCé»å®³å€ãäžã§åäžã®æŽ»æ§å€ã§ãããã
ãªåŠæ¹äžã«ãããããå«ãŸããŠå¥ã ã«æäžããã
ããåã¯ååç©ãšAADCé»å®³å€ã®äž¡æ¹ã掻æ§å€
ãšããŠå«ãã§ããåŠæ¹å€ãšããŠããããäžç·ã«æ
äžã§ãããäž¡æ¹ã®è¬å€ãåäžã®åŠæ¹äžã«å«ãŸããŠ
ããæåè¬å€ã®çžå¯Ÿçãªéã¯äœ¿çšãããåã ã®å
åç©ã«ãã€ãŠå€ããããã æ¬çºæã®ååç©ã¯ææã®å¹æãéæããããçš®
çš®ã®ããæ¹ã§æäžã§ãããååç©ã¯åç¬ã§åã¯è£œ
è¬äžèªå®¹ã§ããæ äœåã¯çšéå€ãšçµåãããŠæäž
ã§ãããããã®æ¯çãšè³ªã¯éžã°ããååç©ã®æº¶è§£
床ãšååŠçæ§è³ªãéžæãããæäžçµè·¯åã³æšæºã®
補è¬æ £ç¿ã«ãã€ãŠæ±ºå®ããããååç©ã¯åºåœ¢ã®é©
é圢äŸãã°ã«ãã»ã«å€ãé å€ãç²å€åã¯æ¶²å€åœ¢ã
äŸãã°æº¶æ¶²åã¯æžæ¿æ¶²ã®åœ¢ã§çµå£çã«æäžããã
ããååç©ã¯å殺è溶液åã¯æžæ¿æ¶²ã®åœ¢ã§éçµå£
çã«æ³šå°ãããããåºåœ¢ã®çµå£åœ¢ã¯æ £çšã®è³Šåœ¢å€
äŸãã°ä¹³ç³ãèç³ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ã
æš¹èãåã³é¡äŒŒç©è³ªãå«ã¿ããã液å€ã®çµå£åœ¢ã¯
çš®ã ã®éŠå³å€ãçè²å€ãä¿åå€ãå®å®å€ãå¯æº¶å
å€åã¯æžæ¿å€ãå«ã¿ãããéçµå£è£œå€ã¯æ®ºèãã
æ°Žæ§åã¯éæ°Žæ§ã®æº¶æ¶²åã¯æžæ¿æ¶²ã§ããããã¯
çš®ã ã®ä¿åå€ãå®å®å€ãç·©è¡å€ãå¯æº¶åå€åã¯æž
æ¿å€ãå«ã¿ãããææã«ããå¡©åã¯ã°ã«ã³ãŒã¹ã®
æ§ãªæ·»å å€ã溶液ãç匵ã«ããããã«å ããã
ãã æäžããã掻æ§ååç©ã®éã¯å€åãä»»æã®æå¹
éã§ããããããããã®ååç©ã®åäœé©éã¯äŸã
ã°çŽååç©çŽïŒmgãã100mgè¿ãå«ãããšãåºæ¥ã
äŸãã°æ¥ã ïŒååã¯ãã以äžã®åæ°å¿ èŠã«å¿ããŠ
æäžããããã åäœé©é圢ãšäºãçšèªã¯æ¬æ现æžäžã§ã¯ãçšé
å€åã¯æ äœãšæ··åç©ãšããŠåã¯ä»ã®æ¹æ³ã§äžç·ã«
ããããã掻æ§æåã®éãå«ãã§ããåäžåã¯è€
æ°æäžéãæå³ããæ§ã«äœ¿çšãããäžèšã®éã¯äž
ååã¯ãã以äžã®äºã決ããããåäœãåäžã®æ²»
çæäžã«æ®éã«å¿ èŠãªãã®ã§ããã液å€åã¯å»ã¿
ç®ãã€ããããé å€ã®æ§ãªè€æ°åã®æäžé圢ã®å Ž
åãäžèšã®äºã決ããããåäœã¯ãè€æ°æäžåœ¢ã®
液ïŒmlïŒè¶ããïŒéåã¯å»ç®ãã€ããé å€åœ¢ã®å
ååã¯1/4ã®æ§ãªå°éšåã§ãããã çµæç©ã®é¢ã§æ¬çºæã¯åŒ ãåŒäžR1ã¯
ãã§ããžã¡ããã·ãšã¿ã³ïŒDMEïŒäžã§ïŒâã§æ°Ž
çŽ åãããªãŠã ã®ååšäžã«åŠçããããšã«ãã€ãŠ
ãŠã€ããããåå¿ã«ããç¥ãããæ¹æ³ã§è£œé åºæ¥
ããåŒãåã¯ã®ã±ãã³ã¯æ¢ç¥ååç©
ã§ãããåã¯æ¢ç¥ååç©ããåœæè¡ã§ç¥ãããæ¹
æ³ã«ãã€ãŠåã¯ãã®èªæã®å€æ³ã«ãã€ãŠè£œé åºæ¥
ããäŸãã°åŒã®ååç©ã¯æ¢ç¥æ¹æ³ã§ããã²ã³
åãããŠåŒïŒžåã¯ã®ååç©ã補é ãããå
ã¯é©åœã«çœ®æããããã³ãŒã³ååç©ã¯ããªãŒãã«
ã¯ã©ããåå¿ã䜿çšããŠã¢ã·ã«ååºæ¥ãã åœæ¥è ã«èªèãããããã«ãåŒã®ååç©ã¯è³
éŠæOHåºåã³ã¢ã«ãã¢ãŒNH2åºãæããããã
ã®äžæ¹åã¯äž¡æ¹ã¯ããèªäœç¥ãããæ¹æ³ã§ã¢ã·ã«
ååºæ¥ããåœæè¡ã§ã¢ã«ã«ã³é žåã¯å€©ç¶ã®ã¢ãã
é žããèªå°ãããâã¢ã·ã«åã¯ïŒ¯âã¢ã·ã«åºã
é€ããéé¢âNH2åºåã¯OHåºãçäœå ã§çãã
ããšãç¥ãããŠãããåŸã€ãŠã¢ã·ã«èªå°äœãæ¬çº
æã®ç®çã«äœ¿çšåºæ¥ãããäœãã¢ã·ã«åºã¯çäœå
ã§é€ããæãŸããã¢ããé žãäžããããšãæ¡ä»¶ãš
ãããæãçš®ã®ä»ã®èªå°äœãçäœå ã§å€æãããŠ
éé¢è³éŠæããããã·åã¯Î±âã¢ããåºãçºçã
ãããšãèªèãããããã®æ§ãªèªå°äœã®äŸã¯ïŒâ
ã¢ããâïŒâãããªãâïŒâïŒ3â²ïŒ4â²âã¡ãã¬ã³
ãžãªãã·ããšãã«ïŒâïŒâããã³é žã§ããããŸã
ãšã¹ãã«åã³å¡©ä»¥å€ã®ã«ã«ãã³é žå®èœåºã®æãèª
å°äœãæ¬çºæã®ç®çã«äœ¿çšåºæ¥ãããšãæçœã§ã
ãããã®äŸã¯ç¬¬ïŒçŽã¢ãã³ã第ïŒçŽåã¯ç¬¬ïŒçŽã¢
ã«ãã«ã¢ãã³åã³å€©ç¶ã¢ãã³é žã®Î±åã¯æ«ç«¯
NH2åºã«ãã€ãŠåœ¢æãããã¢ããã§ããããªã
ãªãã°ã¢ããçµåã¯çäœå ã§éè£ãããããšãç¥
ãããŠããããã§ããã åŒã®ååç©ã¯äžæççŽ ååãæãããããšã
ã³ããªããŒãå¯èœã§ãããæ¬çºæã®ååç©ã¯çç©
掻æ§ãšãã³ããªããŒåã¯ã©ã»ãäœã®åœ¢ã§ãã€ãŠã
ãã åŒã®ååç©ã¯æãã©ã»ãçæç©ãåå²ããã
ãšã«ãã€ãŠãåã¯ã©ã»ãäœåºçºç©è³ªãåã¯åæã®
ä»»æã®éœåãã段éã§äžéäœãåå²ããããšã«ã
ã€ãŠçŽç²ãªãšãã³ããªããŒåœ¢ã§åŸããããåå²å®
æœæ³ã¯ååŠã§åšç¥ã§ãããæ¬æ现æžã§æäžç¯å²ã
äžããããããããã¯ã©ã»ãäœã«ãé©çšåºæ¥ãã æŽã«åŒã®ååç©ã¯ïŒŠã§è¡šãããã眮æåºã
R1ã§è¡šããããåºã«å¯Ÿãã·ã¹åã¯ãã©ã³ã¹ã®ã
ãããã®åœ¢ã§ååšåºæ¥ããæ¬çºæã®ååç©ãçŽç²
ãªã·ã¹åã¯ãã©ã³ã¹åœ¢ã§åã¯ãããã®æ··åç©ãšã
ãŠååšãåŸãããšãç解ãããã æãã€çãæ²»çããã®ã«äœ¿çšããæã¯ãåŒã®
ååç©ã®æå¹ãªæäžéã¯äœ¿çšãããåã ã®åå
ç©ãæãã€çã®ã²ã©ããšè³ªãåã³æ²»çãããåã
ã®æ£è ã«ãã€ãŠå€ãã§ããããäžè¬ã«åŒã®åå
ç©ã§æå¹ãªçµæã¯äžæ¥ã«ã€ãçŽ0.5ããçŽ50mgã®
é©éæ°Žæºã§çµå£åã¯éçµå£çã«éæãããã æ²»çæ³ã¯æ¯èŒçäœãé©éã§éå§ãããã¹ãã§ã
ã®åŸé©éã¯ææã®å¹æãéæãããè¿å¢å ãã
ãã AADCé»å®³å€ãæãã€çã®æ²»çã«åŒã®åå
ç©ãšäžç·ã«æäžãããæãAADCé»å®³å€ã®æå¹
æäžéã¯è³äžã§AADC觊åªè±ã«ã«ããã·ã«åã
å®è³ªäžé®æããã«è³å€ã§äžèšååç©ã®AADC觊
åªè±ã«ã«ããã·ã«åãå®è³ªçã«é®æã§ããªããã°
ãªããªããæå¹ãªæäžéã¯ãããããªããã䜿çš
ãããåã ã®ååç©åã³æäžãããææãã€å€ã
ããã©ã°ïŒProdrugïŒã®æäžéã«ãã€ãŠå€ããã§
ããããäžè¬ã«ã«ã«ãããŒããšãããŒã©ãžããã§
ã¯æå¹ãªçµæã¯äžæ¥ã«ä»ãçŽ50ä¹è³500mgã®æäž
éæ°Žæºã§å¥œãŸããã¯çŽ50ä¹è³250mgã®æäžéæ°Žæº
ã§çµå£åã¯éçµå£çã«éæããããäžèšïŒâãã
ã¡ãã«åãããïŒâã¢ããâïŒâïŒçœ®æããšãã«ïŒ
ããããªã³é žã§ã¯ãæå¹ãªçµæã¯äžæ¥ã«ã€ãçŽ
0.1mgä¹è³1000mgã®æäžéæ°Žæºã§çµå£åã¯éçµå£
çã«éæãããã AADCé»å®³å€ã¯åŒã®ååç©ã®æäžãšå®è³ªäž
åæã«ãåã¯ãã®å ã«äžç·ã«æäžãããããåã«
æäžãããæãAADCé»å®³å€ã¯æäžã®çµè·¯ãšæ²»
çãããŠããçç¶ã®ã²ã©ãã«ãã€ãŠå ç«ã€ããšïŒ
æéè¿ã®éã«äžããããããšãã§ããã AADCé»å®³å€ãšçµã¿åãããŠäœ¿çšããããšã
ã¯ãåŒã®ååç©ãšAADCé»å®³å€ã¯ãååç©å
ã¯AADCé»å®³å€ãäžã§åäžã®æŽ»æ§å€ã§ãããã
ãªåŠæ¹äžã«ãããããå«ãŸããŠå¥ã ã«æäžããã
ããåã¯ååç©ãšAADCé»å®³å€ã®äž¡æ¹ã掻æ§å€
ãšããŠå«ãã§ããåŠæ¹å€ãšããŠããããäžç·ã«æ
äžã§ãããäž¡æ¹ã®è¬å€ãåäžã®åŠæ¹äžã«å«ãŸããŠ
ããæåè¬å€ã®çžå¯Ÿçãªéã¯äœ¿çšãããåã ã®å
åç©ã«ãã€ãŠå€ããããã æ¬çºæã®ååç©ã¯ææã®å¹æãéæããããçš®
çš®ã®ããæ¹ã§æäžã§ãããååç©ã¯åç¬ã§åã¯è£œ
è¬äžèªå®¹ã§ããæ äœåã¯çšéå€ãšçµåãããŠæäž
ã§ãããããã®æ¯çãšè³ªã¯éžã°ããååç©ã®æº¶è§£
床ãšååŠçæ§è³ªãéžæãããæäžçµè·¯åã³æšæºã®
補è¬æ £ç¿ã«ãã€ãŠæ±ºå®ããããååç©ã¯åºåœ¢ã®é©
é圢äŸãã°ã«ãã»ã«å€ãé å€ãç²å€åã¯æ¶²å€åœ¢ã
äŸãã°æº¶æ¶²åã¯æžæ¿æ¶²ã®åœ¢ã§çµå£çã«æäžããã
ããååç©ã¯å殺è溶液åã¯æžæ¿æ¶²ã®åœ¢ã§éçµå£
çã«æ³šå°ãããããåºåœ¢ã®çµå£åœ¢ã¯æ £çšã®è³Šåœ¢å€
äŸãã°ä¹³ç³ãèç³ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ã
æš¹èãåã³é¡äŒŒç©è³ªãå«ã¿ããã液å€ã®çµå£åœ¢ã¯
çš®ã ã®éŠå³å€ãçè²å€ãä¿åå€ãå®å®å€ãå¯æº¶å
å€åã¯æžæ¿å€ãå«ã¿ãããéçµå£è£œå€ã¯æ®ºèãã
æ°Žæ§åã¯éæ°Žæ§ã®æº¶æ¶²åã¯æžæ¿æ¶²ã§ããããã¯
çš®ã ã®ä¿åå€ãå®å®å€ãç·©è¡å€ãå¯æº¶åå€åã¯æž
æ¿å€ãå«ã¿ãããææã«ããå¡©åã¯ã°ã«ã³ãŒã¹ã®
æ§ãªæ·»å å€ã溶液ãç匵ã«ããããã«å ããã
ãã æäžããã掻æ§ååç©ã®éã¯å€åãä»»æã®æå¹
éã§ããããããããã®ååç©ã®åäœé©éã¯äŸã
ã°çŽååç©çŽïŒmgãã100mgè¿ãå«ãããšãåºæ¥ã
äŸãã°æ¥ã ïŒååã¯ãã以äžã®åæ°å¿ èŠã«å¿ããŠ
æäžããããã åäœé©é圢ãšäºãçšèªã¯æ¬æ现æžäžã§ã¯ãçšé
å€åã¯æ äœãšæ··åç©ãšããŠåã¯ä»ã®æ¹æ³ã§äžç·ã«
ããããã掻æ§æåã®éãå«ãã§ããåäžåã¯è€
æ°æäžéãæå³ããæ§ã«äœ¿çšãããäžèšã®éã¯äž
ååã¯ãã以äžã®äºã決ããããåäœãåäžã®æ²»
çæäžã«æ®éã«å¿ èŠãªãã®ã§ããã液å€åã¯å»ã¿
ç®ãã€ããããé å€ã®æ§ãªè€æ°åã®æäžé圢ã®å Ž
åãäžèšã®äºã決ããããåäœã¯ãè€æ°æäžåœ¢ã®
液ïŒmlïŒè¶ããïŒéåã¯å»ç®ãã€ããé å€åœ¢ã®å
ååã¯1/4ã®æ§ãªå°éšåã§ãããã çµæç©ã®é¢ã§æ¬çºæã¯åŒ ãåŒäžR1ã¯
ïŒâã¢ããâïŒâïŒ3â²âããããã·ããšãã«ïŒâ
ïŒâããã³é žïŒä»¥äžAHBAãšããïŒãïŒâã¢ãã
âïŒâãã«ãªãâïŒâïŒ3â²âããããã·ããšãã«ïŒ
âïŒâããã³é žïŒä»¥äžAFHBAãšããïŒåã³ïŒâ
ã¢ããâïŒâãã«ãªãâïŒâïŒ3â²âããããã·â
ïŒâã¡ããã·ããšãã«ïŒâïŒâããã³é žïŒä»¥äž
AFMBAãšããïŒã次ã®ããã«è©Šéšããã  ã€ã³ãããè©Šéš AHBAåã¯AFHBAãéšåçã«ç²Ÿè£œãããè±
è èAADCãšäžç·ã«37ãã§ïŒæéãŸã§çš®ã ã®æé
ã«å¹é€ãããHPLCåæã§ãïŒæéã«åååç©
ïŒDLâæ··åç©ïŒã¯50ïŒ ã®è±ã«ã«ããã·ã«åãå
ãã察å¿ããã¢ãªã«ã¢ãã³ãããããïŒâïŒ3â²â
ããããã·ïŒããšãã«ã¢ãªã«ã¢ãã³åã¯ïŒâ
ïŒ3â²âããããã·ïŒããšãã«âïŒâãã«ãªãã¢ãª
ã«ã¢ãã³ããçããããšã瀺ãããã10ÎŒMαâ
ã¢ããã«ãªãã¡ãã«âããŒãïŒMFMDïŒ
ïŒAADCé»æ¢å€ïŒã®ååšäžã«å®éšãããè¿ããšã
è±ã«ã«ããã·ã«åã¯èŠãããªãã€ãã è±ã«ã«ããã·ã«åçæç©ã¯ã€ã³ãããã§MAO
ã®æéã«äŸåããäžå¯éçãªé»å®³å€ã§ãããïŒâ
ïŒ3â²âããããã·ïŒããšãã«ã¢ãªã«ã¢ãã³ã®IC50
ã¯10-5ãŸã§ãïŒâïŒ3â²âããããã·ïŒããšãã«â
ïŒâãã«ãªãã¢ãªã«ã¢ãã³ã®IC50ã¯10-9ãŸã§ã
AHBAãšAFHBAã¯MAOã«äžæŽ»æ§ã§ããããå
ã¯éåžžã«åŒ±ãé»å®³å€ã§ããã  çäœå€ïŒãšã¯ã¹ããïŒè©Šéš ã¯ã€ãããã¿ã«AHBAïŒ250mgïŒKgãè ¹èå ïŒ
ã®ã¿ãåã¯AHBAïŒ250mgïŒKgãè ¹èå ïŒãšäž
ç·ã«ãAHBAã®30ååã«æäžãããMFMD
ïŒïŒmgïŒKgãè ¹èå ïŒãçµåããŠæ³šå°ãããã¯
ã€ãããã¿ãïŒæéåŸã«ãšæ®ºããè³ãšå¿èã®
MAO掻æ§ïŒåºè³ªãšããŠãã©ãã³ïŒã枬å®ã
ããåç¬æäžãããAHBAã¯ãè³ãšå¿èã§
MAOã®30ïŒ é»å®³ãããããããMFMDãšçµ
åããAHBAã¯è³ã§MAOã®65ïŒ é»å®³ãããã
ããã äœçœ®éžæç圱é¿ã決å®ããããããã€ãã³åº
質ïŒâHFãšéãã€ãã³åºè³ªããšãã«ãšãã«ã¢
ãã³ïŒPEAïŒã䜿çšããŠãã¯ã€ãããã¿è³äž
ã®MAO掻æ§ã決å®ãããMFMDãšçµåããŠ
æäžããAHBAæäžã¯ãã€ãã³MAOïŒïŒâ
HTåºè³ªïŒã82ïŒ ãéãã€ãã³MAOïŒPEAåº
質ïŒã15ïŒ æå¶ããã ã©ããã«AFHBAïŒ0.5mgïŒKgãè ¹èå ïŒã®
ã¿ãåã¯AFHBAïŒ0.5mgïŒKgãè ¹èå ïŒãšäžç·
ã«ãAFHBAã®30ååã«æäžãããMFMD
ïŒ2.0mgïŒKgãè ¹èå ïŒãçµåããŠæäžãããå
ç©ã18æéåŸã«ãšæ®ºããè³ãå¿èåã³èèã®
MAO掻æ§ïŒåºè³ªãšããŠïŒâHTåã³ããšãã
ã«ã¢ãã³ïŒã枬å®ãããè³ã§ã¯ãåç¬æäžãã
ãAFHBAã¯ãã€ãã³MAOã72ïŒ ãéãã€ã
ã³MAOã37ïŒ æå¶ãããMFMDäºååŠçã¯ã
ãã€ãã³MAOé»å®³ãæ¬è³ªçã«äœäžãããªãã€
ããïŒ68ïŒ ïŒãéãã€ãã³MAOé»å®³ã28ïŒ ãŸ
ã§äœäžããããå¿èã§ã¯ãAFHBAã¯ãã€ãã³
MAOã52ïŒ ãéãã€ãã³MAOã44ïŒ é»å®³ã
ãããMFMDäºååŠçã¯ãã€ãã³MAOé»å®³
ã18ïŒ ã«ãéãã€ãã³é»å®³ãïŒïŒ ã«äœäžãã
ããèèã§ã¯ãAFHBAã®ã¿ã«ããMAOé»å®³
ã¯29ïŒ ïŒãã€ãã³ïŒãš38ïŒ ïŒéãã€ãã³ïŒã§ã
ã€ãããMFMDäºååŠçã¯MAOé»å®³ãå šã
å°ããã ã«ãŒãããŒãïŒ50mgïŒKgãè ¹èå ïŒã䜿çšã
ãŠãAFHBAã«ããäžã®å®éšãããè¿ããšã
AADCé»å®³å€ã¯å¿èã§MAOé»å®³ã«å¯ŸããŠ
MFMDïŒ2.0mgïŒKgãè ¹èå ïŒãšåãä¿è·å¹æã
ããããããçµå£æäžã«ããAFHBA掻æ§ã瀺ã
ããã«ãã©ããã«çš®ã ã®æäžéã®ååç©ã匷å¶ç
ã«é£ã¹ããã18æéåŸã«ãšæ®ºãããïŒâHTåã³
ããšããã«ã¢ãã³ïŒPEAïŒãåºè³ªãšããŠäœ¿çšã
ãŠè³å ã®MAO掻æ§ã枬å®ããã次ã®çµæãåŸã
ããã MAOé»å®³ïŒïŒ ïŒ æäžéïŒmgïŒKgïŒ ãã€ãã³ éãã€ãã³ 0.5 63 41 1.0 71 64 2.5 95 83 ã©ããã«AFMBAïŒ100mgïŒKgãè ¹èå ïŒã
泚å°ãã18æéåŸã«ãšæ®ºãããïŒâHTåã³
PEAã䜿çšããŠãè³ãå¿èåã³èèã®MAO掻
æ§ã決å®ããã次ã®çµæãåŸãããã MAOé»å®³ïŒïŒ ïŒ ãã€ãã³ éãã€ãã³ è³ 16 40 å¿è 18 46 èè ïŒ 11 ã©ããã«ãšãã«ãšã¹ãã«ãšããŠAHBAïŒ334
mgïŒKgãè ¹èå ïŒã®ã¿ãåã¯ããã«AHBAãš
ãã«ãšã¹ãã«æäžå30åã«äžããããã«ãŒãã
ãŒãïŒ100mgïŒKgãè ¹èå ïŒãçµåãããŠæ³šå°
ãããåç©ãïŒæéåŸã«ãšæ®ºãããïŒâHTãš
PEAãåºè³ªãšããŠäœ¿çšããŠãè³ã®MAO掻æ§ã
決å®ããã次ã®çµæãåŸãããã
ïŒâããã³é žïŒä»¥äžAHBAãšããïŒãïŒâã¢ãã
âïŒâãã«ãªãâïŒâïŒ3â²âããããã·ããšãã«ïŒ
âïŒâããã³é žïŒä»¥äžAFHBAãšããïŒåã³ïŒâ
ã¢ããâïŒâãã«ãªãâïŒâïŒ3â²âããããã·â
ïŒâã¡ããã·ããšãã«ïŒâïŒâããã³é žïŒä»¥äž
AFMBAãšããïŒã次ã®ããã«è©Šéšããã  ã€ã³ãããè©Šéš AHBAåã¯AFHBAãéšåçã«ç²Ÿè£œãããè±
è èAADCãšäžç·ã«37ãã§ïŒæéãŸã§çš®ã ã®æé
ã«å¹é€ãããHPLCåæã§ãïŒæéã«åååç©
ïŒDLâæ··åç©ïŒã¯50ïŒ ã®è±ã«ã«ããã·ã«åãå
ãã察å¿ããã¢ãªã«ã¢ãã³ãããããïŒâïŒ3â²â
ããããã·ïŒããšãã«ã¢ãªã«ã¢ãã³åã¯ïŒâ
ïŒ3â²âããããã·ïŒããšãã«âïŒâãã«ãªãã¢ãª
ã«ã¢ãã³ããçããããšã瀺ãããã10ÎŒMαâ
ã¢ããã«ãªãã¡ãã«âããŒãïŒMFMDïŒ
ïŒAADCé»æ¢å€ïŒã®ååšäžã«å®éšãããè¿ããšã
è±ã«ã«ããã·ã«åã¯èŠãããªãã€ãã è±ã«ã«ããã·ã«åçæç©ã¯ã€ã³ãããã§MAO
ã®æéã«äŸåããäžå¯éçãªé»å®³å€ã§ãããïŒâ
ïŒ3â²âããããã·ïŒããšãã«ã¢ãªã«ã¢ãã³ã®IC50
ã¯10-5ãŸã§ãïŒâïŒ3â²âããããã·ïŒããšãã«â
ïŒâãã«ãªãã¢ãªã«ã¢ãã³ã®IC50ã¯10-9ãŸã§ã
AHBAãšAFHBAã¯MAOã«äžæŽ»æ§ã§ããããå
ã¯éåžžã«åŒ±ãé»å®³å€ã§ããã  çäœå€ïŒãšã¯ã¹ããïŒè©Šéš ã¯ã€ãããã¿ã«AHBAïŒ250mgïŒKgãè ¹èå ïŒ
ã®ã¿ãåã¯AHBAïŒ250mgïŒKgãè ¹èå ïŒãšäž
ç·ã«ãAHBAã®30ååã«æäžãããMFMD
ïŒïŒmgïŒKgãè ¹èå ïŒãçµåããŠæ³šå°ãããã¯
ã€ãããã¿ãïŒæéåŸã«ãšæ®ºããè³ãšå¿èã®
MAO掻æ§ïŒåºè³ªãšããŠãã©ãã³ïŒã枬å®ã
ããåç¬æäžãããAHBAã¯ãè³ãšå¿èã§
MAOã®30ïŒ é»å®³ãããããããMFMDãšçµ
åããAHBAã¯è³ã§MAOã®65ïŒ é»å®³ãããã
ããã äœçœ®éžæç圱é¿ã決å®ããããããã€ãã³åº
質ïŒâHFãšéãã€ãã³åºè³ªããšãã«ãšãã«ã¢
ãã³ïŒPEAïŒã䜿çšããŠãã¯ã€ãããã¿è³äž
ã®MAO掻æ§ã決å®ãããMFMDãšçµåããŠ
æäžããAHBAæäžã¯ãã€ãã³MAOïŒïŒâ
HTåºè³ªïŒã82ïŒ ãéãã€ãã³MAOïŒPEAåº
質ïŒã15ïŒ æå¶ããã ã©ããã«AFHBAïŒ0.5mgïŒKgãè ¹èå ïŒã®
ã¿ãåã¯AFHBAïŒ0.5mgïŒKgãè ¹èå ïŒãšäžç·
ã«ãAFHBAã®30ååã«æäžãããMFMD
ïŒ2.0mgïŒKgãè ¹èå ïŒãçµåããŠæäžãããå
ç©ã18æéåŸã«ãšæ®ºããè³ãå¿èåã³èèã®
MAO掻æ§ïŒåºè³ªãšããŠïŒâHTåã³ããšãã
ã«ã¢ãã³ïŒã枬å®ãããè³ã§ã¯ãåç¬æäžãã
ãAFHBAã¯ãã€ãã³MAOã72ïŒ ãéãã€ã
ã³MAOã37ïŒ æå¶ãããMFMDäºååŠçã¯ã
ãã€ãã³MAOé»å®³ãæ¬è³ªçã«äœäžãããªãã€
ããïŒ68ïŒ ïŒãéãã€ãã³MAOé»å®³ã28ïŒ ãŸ
ã§äœäžããããå¿èã§ã¯ãAFHBAã¯ãã€ãã³
MAOã52ïŒ ãéãã€ãã³MAOã44ïŒ é»å®³ã
ãããMFMDäºååŠçã¯ãã€ãã³MAOé»å®³
ã18ïŒ ã«ãéãã€ãã³é»å®³ãïŒïŒ ã«äœäžãã
ããèèã§ã¯ãAFHBAã®ã¿ã«ããMAOé»å®³
ã¯29ïŒ ïŒãã€ãã³ïŒãš38ïŒ ïŒéãã€ãã³ïŒã§ã
ã€ãããMFMDäºååŠçã¯MAOé»å®³ãå šã
å°ããã ã«ãŒãããŒãïŒ50mgïŒKgãè ¹èå ïŒã䜿çšã
ãŠãAFHBAã«ããäžã®å®éšãããè¿ããšã
AADCé»å®³å€ã¯å¿èã§MAOé»å®³ã«å¯ŸããŠ
MFMDïŒ2.0mgïŒKgãè ¹èå ïŒãšåãä¿è·å¹æã
ããããããçµå£æäžã«ããAFHBA掻æ§ã瀺ã
ããã«ãã©ããã«çš®ã ã®æäžéã®ååç©ã匷å¶ç
ã«é£ã¹ããã18æéåŸã«ãšæ®ºãããïŒâHTåã³
ããšããã«ã¢ãã³ïŒPEAïŒãåºè³ªãšããŠäœ¿çšã
ãŠè³å ã®MAO掻æ§ã枬å®ããã次ã®çµæãåŸã
ããã MAOé»å®³ïŒïŒ ïŒ æäžéïŒmgïŒKgïŒ ãã€ãã³ éãã€ãã³ 0.5 63 41 1.0 71 64 2.5 95 83 ã©ããã«AFMBAïŒ100mgïŒKgãè ¹èå ïŒã
泚å°ãã18æéåŸã«ãšæ®ºãããïŒâHTåã³
PEAã䜿çšããŠãè³ãå¿èåã³èèã®MAO掻
æ§ã決å®ããã次ã®çµæãåŸãããã MAOé»å®³ïŒïŒ ïŒ ãã€ãã³ éãã€ãã³ è³ 16 40 å¿è 18 46 èè ïŒ 11 ã©ããã«ãšãã«ãšã¹ãã«ãšããŠAHBAïŒ334
mgïŒKgãè ¹èå ïŒã®ã¿ãåã¯ããã«AHBAãš
ãã«ãšã¹ãã«æäžå30åã«äžããããã«ãŒãã
ãŒãïŒ100mgïŒKgãè ¹èå ïŒãçµåãããŠæ³šå°
ãããåç©ãïŒæéåŸã«ãšæ®ºãããïŒâHTãš
PEAãåºè³ªãšããŠäœ¿çšããŠãè³ã®MAO掻æ§ã
決å®ããã次ã®çµæãåŸãããã
ãè¡šã
ãããŒã
NïŒ ãã€ãã³æ§ã®ãã®ãæå³ãã
ã
 çäœå ïŒã€ã³ããïŒè©Šéš ã©ããã«ãAFHBAïŒ0.5mgïŒKgãè ¹èå ïŒã®
ã¿ãåã¯AFHBAïŒ0.5mgïŒKgãè ¹èå ïŒãšäžç·
ã«ãAFHBAã®30ååã«äžããããMFMDïŒïŒ
mgïŒKgãè ¹èå ïŒåã¯ã«ãŒãããŒãïŒ50mgïŒKgã
è ¹èå ïŒãçµåãããŠæ³šå°ãããã©ããã18æé
åŸã«ãšæ®ºããè³å ã®ãããã³ãDOPACãïŒâ
HTåã³ïŒâHIAAæ¿åºŠã枬å®ããã次ã®çµæã
åŸãããã
NïŒ ãã€ãã³æ§ã®ãã®ãæå³ãã
ã
 çäœå ïŒã€ã³ããïŒè©Šéš ã©ããã«ãAFHBAïŒ0.5mgïŒKgãè ¹èå ïŒã®
ã¿ãåã¯AFHBAïŒ0.5mgïŒKgãè ¹èå ïŒãšäžç·
ã«ãAFHBAã®30ååã«äžããããMFMDïŒïŒ
mgïŒKgãè ¹èå ïŒåã¯ã«ãŒãããŒãïŒ50mgïŒKgã
è ¹èå ïŒãçµåãããŠæ³šå°ãããã©ããã18æé
åŸã«ãšæ®ºããè³å ã®ãããã³ãDOPACãïŒâ
HTåã³ïŒâHIAAæ¿åºŠã枬å®ããã次ã®çµæã
åŸãããã
ãè¡šã
ãŒã
å¥ã®å®éšã§ãã©ããã«çš®ã ã®æäžéã®AFHBA
ãçµå£æäžãããã©ããã18æéåŸã«ãšæ®ºããè³
å ã®ãããã³ãDOPACãïŒâHTåã³ïŒâ
HIAAæ¿åºŠã枬å®ããã次ã®çµæãåŸãããã
å¥ã®å®éšã§ãã©ããã«çš®ã ã®æäžéã®AFHBA
ãçµå£æäžãããã©ããã18æéåŸã«ãšæ®ºããè³
å ã®ãããã³ãDOPACãïŒâHTåã³ïŒâ
HIAAæ¿åºŠã枬å®ããã次ã®çµæãåŸãããã
 ããŠã¹
ïŒ çµå£åã³è
¹è
å
AFHBAã®LD50ãCDâïŒããŠã¹äžã§èšç®ã
ããè©Šéšã®æåã®éšåã«æŒããŠããŠã¹ïŒïŒå¹ïŒ
æ§ïŒæäžïŒã«æé£ã«ãã€ãŠ200ã1600mgïŒKgã®
AFHBAã®åäžçµå£æäžç©ãäžããããè¬ç©ç©è³ª
ã¯èžçæ°Žäžã«æº¶è§£ããŠäžããããããã®æäžã«æŒ
ããŠãã»ãã®å°ãã®æ»äº¡ããèªããããªãã€ãã®
ã§çµå£æ¯æ§ããªãããšãã貧匱ãªèè žåžåã«å¯Ÿã
äºæ¬¡çãªãã®ãã©ããã決å®ããçºã«1000mgïŒKg
ã®AFHBAãïŒå¹ã®è¿œå çãªããŠã¹ïŒæ§ã«äžã
ãããã®åŸã2000ã3000åã³5000mgïŒKgã®çµå£æ
äžéãäžãããããæäžã®åŸããã¹ãŠã®åç©ãïŒ
é±é芳枬ããã泚ç®ã«å€ããèšåºçãªèŠ³æž¬ã«ã¯ã
400mgïŒKg以äžã®æäžã«æŒããæžå°ããèªçºçãª
掻åã1200åã³1600mgïŒKgã«æŒããæ»æçãªæ
åãåã³3000mgïŒKgã«æŒããäŒé°ã®ãœã€ãªã³ã°
ïŒåã§æ±ããããšïŒãå«ãŸãããééå¢å ã®å²å
ã¯1600mgïŒKg以äžã®è¬ç©æäžã«ãã€ãŠåœ±é¿ãåã
ãªãããã§ããã5000mgïŒKgãŸã§ã®æäžéã§ãã
圱é¿ãåããªãããã§ãããç延ã³ãåç©ã¯å¯Ÿç §
ã®ãããšäŒŒããããªå²åã§ééã®å¢å ãç¶ããã äžèšããæšæž¬ããŠãCDâïŒããŠã¹äžã®
AFHBAã®æ¥æ§æ¯æ§ã¯äœãã1600mgïŒKg以äžã®çµ
å£æäžã«æŒããŠã10å¹ã®ããŠã¹ã®ãã¡ãè¬ç©æäž
ã®åŸæ»ãã ãã®ã¯ïŒå¹ãè¶ããªãã1000mgïŒKgã
è ¹è å æäžããããšãã10å¹ã®ããŠã¹ã®ãã¡ãã
ïŒå¹ãæ»ã«ã貧匱ãªçµå£åžåã®ããã§æ¯æ§ã®äœã
çšåºŠãšãªã€ãŠããã®ã§ã¯ãªãããšã瀺åããŠã
ããã©ããã®å ŽåïŒäžèšåç §ïŒè èã¯è¬ç©ã«èªçº
ãããæ¯æ§ã®äž»èŠãªå Žæã§ããããã§ããã倧é
æã«èšã€ãŠãèªçºçã«æ»ã«ããã€ãŠããã»ãšãã©
ã®ããŠã¹ã®è èã¯ã¯ã€ããããéçœãç®è³ªåã³ïŒ
åã¯æãè²ã®é«è³ªãæããŠãããæ¥æ§ã®è èã®çŽ°
管ã®å£æ»ããçµå£çã«400mgïŒKg以äžåã¯è ¹è å
ã§1000mgïŒKgã®è èåçäžã«çŽ°èåŠçã«èŠåºãã
ããæ¥æ§ã®çŽ°ç®¡ã®å£æ»ã«å¯Ÿãäºæ¬¡çã§ããæ¥æ§ã®
è èã®äžå šã¯AFHBAã®åäžçµå£æäžãåã¯è ¹è
å æäžã«ç¶ãããŠã¹ã®æ»ã®äž»èŠãªå åã§ããããš
ãèãããããçåãããã®ã¯æäžåŸ14æ¥ã®æ»äœ
解åã«æŒããŠã倧éæã«ã¿ãåŠçã«é¢é£ããç°åžž
æ§ãæããªãã€ããLD50å€ã¯éã«å¯ŸããŠ3008
mgïŒKgïŒ256ã5759mgïŒKgã®95ïŒ ä¿¡é ŒéçïŒããã
ãŠçã«å¯ŸããŠ4650mgïŒKgïŒïŒã1199mgïŒKgã®95ïŒ
ä¿¡é ŒéçïŒã§ãã€ãïŒåŸã®è¡šïŒãåç §ïŒã  ã©ãã ïŒ çµå£ AFHBAã®æ¥æ§çµå£æ¯æ§ã200ã400ã500ã635
åã³800mgïŒKgã®æäžéãçšããŠãã¹ãã©ãŒã°â
ããŠã¬ãŒã©ããäžã§è©äŸ¡ãããè¬ç©ç©è³ªãèžçæ°Ž
äžã«æº¶è§£ããæé£ã«ããïŒå¹ã®ã©ããïŒæ§ïŒæäž
éã«å¯Ÿãæäžãããã©ããã次ã«åèšã§14æ¥é芳
枬ãããæžå°ãã掻æ§ãæžå°ããé£ç©æ¶è²»ãåã³
æãã€ç©ã®æåºéã錻åã®ãã«ãã€ãªã³ã«ããæ
è²ãå šãŠã®æäžæ°Žæºã§èµ·ãããäŒé°ãåã§æ±ãã
ãšã500mgïŒKg以äžã®æäžéã§èªããããã800
mgïŒKgã§æ»ææ§ãèªãããããèšåºçãªåŸ®åã®é
å§ããæäžåŸãïŒãïŒæ¥ã§çããïŒãïŒæ¥éç¶ã
ããè¬ç©æäžåŸãæ»äº¡ãïŒãïŒæ¥éã§çãããç
åè ã¯ïŒæ¥è¿ã«æ£åžžã«èŠããã éã¯äœéå¢å ã«å¯Ÿããè¬ç©æäžã®æªåœ±é¿ã«å¯Ÿ
ããããæåæ§ã§ããããã«èŠããã400mgïŒKg
ã«ãããŠãäœéã®å¢å ãéã«æŒããŠæžå°ããäžæ¹
500mgïŒKgã§äœéã®æžå°ãçãããéã«æŒããŠã¯ã
400mgïŒKgã¯äœéå¢å ã«åœ±é¿ãäžãããäžæ¹500
mgïŒKgã¯äœéå¢å ã®å²åã®æžå°ãçããïŒäœéã®
æžå°ã¯ç¡ãã€ãïŒã635mgïŒKgåã³800mgïŒKgã®æ
äžéã¯ãå šæ¬çã«èŽæ»çã§ãããäœéå¢å ã«å¯Ÿã
ã圱é¿ã¯è©äŸ¡ã§ããªãã€ãã æ€æ»ã®ç 究ã«ãã€ãŠãè èãæ¯æ§ã®äž»èŠãªå Žæ
ã§ããããšãæãããšãªã€ãã500mgïŒKg以äžã®
æäžéã§ã¯ã»ãšãã©ã®åç©ïŒèªç¶ã«æ»ã«ããã€ãŠ
ãããã®ãšçååç©ã®äž¡æ¹ïŒã¯ãéçœãç®è³ªå
ã³ïŒåã¯æãè²ã®é«è³ªãå«ãããè èæ¯æ§ã®åŸ®å
ãæããããã¯800mgïŒKgã§æ¥æ§ã®çŽ°ç®¡ã®å£æ»ã«
é²è¡ãããè èã®å£åã¯æ»äº¡ã®åå ãšãªãäž»èŠãª
å åã§ããããã«èŠãããèºåã³èèã®æ¬è¡ãè
è ã®èšåŒµãç²èã®ããã°ã¿ïŒèã®æœ°çãèªãã
ããäž»ãšããŠ635åã³800mgïŒKgã§èªãããããé
åã³éã®äž¡æ¹ã«å¯ŸããLD50ã525mgïŒKgãšèšç®ã
ããããã¯330ã720mgïŒKgã®95ïŒ ä¿¡é Œéçã§ãã€
ãïŒåŸã®è¡šïŒãåç §ïŒã ïŒ éèå AFHBAã«å¯Ÿããæ¥æ§ã®éèå LD50枬å®ãã¹
ãã©ãŠã°âããŠã¬ã€ã©ããäžã§ãªããããïŒå¹ã®
ã©ããïŒæ§ïŒæäžéã«AFHBAãæäžããïŒèžç
æ°Žã«æº¶è§£ïŒã100ã200ã300ãåã³400mgïŒKgã®å
äžæäžéãå°Ÿã®éèã«æ³šå°ãããããŠã©ããã14
æ¥éã¢ãã¿ãŒãããæžå°ããèªçºçãªæŽ»åã300
mgïŒKg以äžã®æäžéã§çããæäžåŸ24æéããå§
ã€ãŠãïŒæ¥éç¶ãããé£ç©ã®æ¶è²»ãææ³ç©ã®æåº
éã300åã³400mgïŒKgã§æžå°ãããäœéå¢å ã®å²
åã¯ãéåã³éã®äž¡æ¹ã§200mgïŒKg以äžã®æäžé
ã§æžå°ããã 100mgïŒKgã®éèå æäžãäžããããã©ããã§
æ»äº¡ã¯çããªãã€ããå šãŠã®ä»ã®çŸ€ã«æŒããŠãã
ããã®è¬ç©æäžã«å¯Ÿãäºæ¬¡çãªæ»ã«ããã€ãŠãã
ã©ããã¯æäžåŸïŒãïŒæ¥ã§æ»äº¡ãããçµå£æäžã®
å Žåã®ããã«ã倧éæãªç çåŠçãªç 究ã«ãã€ãŠ
è èãæ¯æ§ã®äž»èŠãªå Žæã§ããããšãå€æããã
èªçºçã«æ»ã«ããã€ãŠããå šãŠã®åç©äžã§ãè è
ã®ç®è³ªã¯éçœãäžæ¹ãé«è³ªã¯æãè²ãããŠããã
åŸã€ãŠãçµå£æäžã®å Žåã®æ§ã«ãè èã®å£åãã
ããã®åç©ã®æ»äº¡ã«å¯äžããäž»èŠãªèŠå ã§ããã
ãã«èŠãããæŽã«äœå¹ãã®åç©ãèè ã®ããããª
èšåŒµãåã³èèã®å€è²ã瀺ãããLD50å€ïŒåã³
95ïŒ ä¿¡é ŒéçïŒããéã«ã€ããŠ308ïŒ161ã454ïŒ
mgïŒKgããããŠéã«ã€ããŠ241ïŒ142ã340ïŒmgïŒKg
ãèšç®ããïŒè¡šïŒãåç §ïŒã
ããè©Šéšã®æåã®éšåã«æŒããŠããŠã¹ïŒïŒå¹ïŒ
æ§ïŒæäžïŒã«æé£ã«ãã€ãŠ200ã1600mgïŒKgã®
AFHBAã®åäžçµå£æäžç©ãäžããããè¬ç©ç©è³ª
ã¯èžçæ°Žäžã«æº¶è§£ããŠäžããããããã®æäžã«æŒ
ããŠãã»ãã®å°ãã®æ»äº¡ããèªããããªãã€ãã®
ã§çµå£æ¯æ§ããªãããšãã貧匱ãªèè žåžåã«å¯Ÿã
äºæ¬¡çãªãã®ãã©ããã決å®ããçºã«1000mgïŒKg
ã®AFHBAãïŒå¹ã®è¿œå çãªããŠã¹ïŒæ§ã«äžã
ãããã®åŸã2000ã3000åã³5000mgïŒKgã®çµå£æ
äžéãäžãããããæäžã®åŸããã¹ãŠã®åç©ãïŒ
é±é芳枬ããã泚ç®ã«å€ããèšåºçãªèŠ³æž¬ã«ã¯ã
400mgïŒKg以äžã®æäžã«æŒããæžå°ããèªçºçãª
掻åã1200åã³1600mgïŒKgã«æŒããæ»æçãªæ
åãåã³3000mgïŒKgã«æŒããäŒé°ã®ãœã€ãªã³ã°
ïŒåã§æ±ããããšïŒãå«ãŸãããééå¢å ã®å²å
ã¯1600mgïŒKg以äžã®è¬ç©æäžã«ãã€ãŠåœ±é¿ãåã
ãªãããã§ããã5000mgïŒKgãŸã§ã®æäžéã§ãã
圱é¿ãåããªãããã§ãããç延ã³ãåç©ã¯å¯Ÿç §
ã®ãããšäŒŒããããªå²åã§ééã®å¢å ãç¶ããã äžèšããæšæž¬ããŠãCDâïŒããŠã¹äžã®
AFHBAã®æ¥æ§æ¯æ§ã¯äœãã1600mgïŒKg以äžã®çµ
å£æäžã«æŒããŠã10å¹ã®ããŠã¹ã®ãã¡ãè¬ç©æäž
ã®åŸæ»ãã ãã®ã¯ïŒå¹ãè¶ããªãã1000mgïŒKgã
è ¹è å æäžããããšãã10å¹ã®ããŠã¹ã®ãã¡ãã
ïŒå¹ãæ»ã«ã貧匱ãªçµå£åžåã®ããã§æ¯æ§ã®äœã
çšåºŠãšãªã€ãŠããã®ã§ã¯ãªãããšã瀺åããŠã
ããã©ããã®å ŽåïŒäžèšåç §ïŒè èã¯è¬ç©ã«èªçº
ãããæ¯æ§ã®äž»èŠãªå Žæã§ããããã§ããã倧é
æã«èšã€ãŠãèªçºçã«æ»ã«ããã€ãŠããã»ãšãã©
ã®ããŠã¹ã®è èã¯ã¯ã€ããããéçœãç®è³ªåã³ïŒ
åã¯æãè²ã®é«è³ªãæããŠãããæ¥æ§ã®è èã®çŽ°
管ã®å£æ»ããçµå£çã«400mgïŒKg以äžåã¯è ¹è å
ã§1000mgïŒKgã®è èåçäžã«çŽ°èåŠçã«èŠåºãã
ããæ¥æ§ã®çŽ°ç®¡ã®å£æ»ã«å¯Ÿãäºæ¬¡çã§ããæ¥æ§ã®
è èã®äžå šã¯AFHBAã®åäžçµå£æäžãåã¯è ¹è
å æäžã«ç¶ãããŠã¹ã®æ»ã®äž»èŠãªå åã§ããããš
ãèãããããçåãããã®ã¯æäžåŸ14æ¥ã®æ»äœ
解åã«æŒããŠã倧éæã«ã¿ãåŠçã«é¢é£ããç°åžž
æ§ãæããªãã€ããLD50å€ã¯éã«å¯ŸããŠ3008
mgïŒKgïŒ256ã5759mgïŒKgã®95ïŒ ä¿¡é ŒéçïŒããã
ãŠçã«å¯ŸããŠ4650mgïŒKgïŒïŒã1199mgïŒKgã®95ïŒ
ä¿¡é ŒéçïŒã§ãã€ãïŒåŸã®è¡šïŒãåç §ïŒã  ã©ãã ïŒ çµå£ AFHBAã®æ¥æ§çµå£æ¯æ§ã200ã400ã500ã635
åã³800mgïŒKgã®æäžéãçšããŠãã¹ãã©ãŒã°â
ããŠã¬ãŒã©ããäžã§è©äŸ¡ãããè¬ç©ç©è³ªãèžçæ°Ž
äžã«æº¶è§£ããæé£ã«ããïŒå¹ã®ã©ããïŒæ§ïŒæäž
éã«å¯Ÿãæäžãããã©ããã次ã«åèšã§14æ¥é芳
枬ãããæžå°ãã掻æ§ãæžå°ããé£ç©æ¶è²»ãåã³
æãã€ç©ã®æåºéã錻åã®ãã«ãã€ãªã³ã«ããæ
è²ãå šãŠã®æäžæ°Žæºã§èµ·ãããäŒé°ãåã§æ±ãã
ãšã500mgïŒKg以äžã®æäžéã§èªããããã800
mgïŒKgã§æ»ææ§ãèªãããããèšåºçãªåŸ®åã®é
å§ããæäžåŸãïŒãïŒæ¥ã§çããïŒãïŒæ¥éç¶ã
ããè¬ç©æäžåŸãæ»äº¡ãïŒãïŒæ¥éã§çãããç
åè ã¯ïŒæ¥è¿ã«æ£åžžã«èŠããã éã¯äœéå¢å ã«å¯Ÿããè¬ç©æäžã®æªåœ±é¿ã«å¯Ÿ
ããããæåæ§ã§ããããã«èŠããã400mgïŒKg
ã«ãããŠãäœéã®å¢å ãéã«æŒããŠæžå°ããäžæ¹
500mgïŒKgã§äœéã®æžå°ãçãããéã«æŒããŠã¯ã
400mgïŒKgã¯äœéå¢å ã«åœ±é¿ãäžãããäžæ¹500
mgïŒKgã¯äœéå¢å ã®å²åã®æžå°ãçããïŒäœéã®
æžå°ã¯ç¡ãã€ãïŒã635mgïŒKgåã³800mgïŒKgã®æ
äžéã¯ãå šæ¬çã«èŽæ»çã§ãããäœéå¢å ã«å¯Ÿã
ã圱é¿ã¯è©äŸ¡ã§ããªãã€ãã æ€æ»ã®ç 究ã«ãã€ãŠãè èãæ¯æ§ã®äž»èŠãªå Žæ
ã§ããããšãæãããšãªã€ãã500mgïŒKg以äžã®
æäžéã§ã¯ã»ãšãã©ã®åç©ïŒèªç¶ã«æ»ã«ããã€ãŠ
ãããã®ãšçååç©ã®äž¡æ¹ïŒã¯ãéçœãç®è³ªå
ã³ïŒåã¯æãè²ã®é«è³ªãå«ãããè èæ¯æ§ã®åŸ®å
ãæããããã¯800mgïŒKgã§æ¥æ§ã®çŽ°ç®¡ã®å£æ»ã«
é²è¡ãããè èã®å£åã¯æ»äº¡ã®åå ãšãªãäž»èŠãª
å åã§ããããã«èŠãããèºåã³èèã®æ¬è¡ãè
è ã®èšåŒµãç²èã®ããã°ã¿ïŒèã®æœ°çãèªãã
ããäž»ãšããŠ635åã³800mgïŒKgã§èªãããããé
åã³éã®äž¡æ¹ã«å¯ŸããLD50ã525mgïŒKgãšèšç®ã
ããããã¯330ã720mgïŒKgã®95ïŒ ä¿¡é Œéçã§ãã€
ãïŒåŸã®è¡šïŒãåç §ïŒã ïŒ éèå AFHBAã«å¯Ÿããæ¥æ§ã®éèå LD50枬å®ãã¹
ãã©ãŠã°âããŠã¬ã€ã©ããäžã§ãªããããïŒå¹ã®
ã©ããïŒæ§ïŒæäžéã«AFHBAãæäžããïŒèžç
æ°Žã«æº¶è§£ïŒã100ã200ã300ãåã³400mgïŒKgã®å
äžæäžéãå°Ÿã®éèã«æ³šå°ãããããŠã©ããã14
æ¥éã¢ãã¿ãŒãããæžå°ããèªçºçãªæŽ»åã300
mgïŒKg以äžã®æäžéã§çããæäžåŸ24æéããå§
ã€ãŠãïŒæ¥éç¶ãããé£ç©ã®æ¶è²»ãææ³ç©ã®æåº
éã300åã³400mgïŒKgã§æžå°ãããäœéå¢å ã®å²
åã¯ãéåã³éã®äž¡æ¹ã§200mgïŒKg以äžã®æäžé
ã§æžå°ããã 100mgïŒKgã®éèå æäžãäžããããã©ããã§
æ»äº¡ã¯çããªãã€ããå šãŠã®ä»ã®çŸ€ã«æŒããŠãã
ããã®è¬ç©æäžã«å¯Ÿãäºæ¬¡çãªæ»ã«ããã€ãŠãã
ã©ããã¯æäžåŸïŒãïŒæ¥ã§æ»äº¡ãããçµå£æäžã®
å Žåã®ããã«ã倧éæãªç çåŠçãªç 究ã«ãã€ãŠ
è èãæ¯æ§ã®äž»èŠãªå Žæã§ããããšãå€æããã
èªçºçã«æ»ã«ããã€ãŠããå šãŠã®åç©äžã§ãè è
ã®ç®è³ªã¯éçœãäžæ¹ãé«è³ªã¯æãè²ãããŠããã
åŸã€ãŠãçµå£æäžã®å Žåã®æ§ã«ãè èã®å£åãã
ããã®åç©ã®æ»äº¡ã«å¯äžããäž»èŠãªèŠå ã§ããã
ãã«èŠãããæŽã«äœå¹ãã®åç©ãèè ã®ããããª
èšåŒµãåã³èèã®å€è²ã瀺ãããLD50å€ïŒåã³
95ïŒ ä¿¡é ŒéçïŒããéã«ã€ããŠ308ïŒ161ã454ïŒ
mgïŒKgããããŠéã«ã€ããŠ241ïŒ142ã340ïŒmgïŒKg
ãèšç®ããïŒè¡šïŒãåç §ïŒã
ãè¡šã
ãè¡šã
ã©ã°ããŠã¬
é 525(330ã720)
ã€)
ã©ãã(ã¹ã éèå é 308(161ã454)
ã©ã°ããŠã¬
é 241(142ã340)
ã€)
LD50å€åã³95ïŒ ä¿¡é Œéçã¯ããŒã¯ãœã³
ïŒBerksonïŒã®æå°ã«ã€äºä¹æ³ã®èšå·è«çåŠé¢æ°
ãçšããŠèšç®ãããããŠæäžåŸ14æ¥å ã«çããæ»
亡ã«åºã¥ããŠããã  ç¿ ïŒ çµå£ AFHBAã®æ¥æ§æ¯æ§ã®å€åãç¿(5)äžã§åŸããïŒ
å¹ã®éããã¢ã«ã¬ã¹ã¢ã³ããŒïŒcynomolgus
monkeyïŒïŒMacaca fascicularisïŒããã®ç 究ã§
çšãããç¿ã¯AFHBAã®10ã160mgïŒKgã®ç¯å²ã®
å¢å ããåäžçµå£æäžããããŒããŒã·ãšã³çã«å
ããïŒéŒ»èæ¿ç®¡æ³ã«ãã溶液åã¯æžæ¿æ¶²ãšããŠæ
äžïŒãè¬ç©ã®åæäžã®åŸãåç©ãæªãèšåºçãªåŸ®
ååã³çç¶ã«ã€ããŠïŒãïŒæ¥é芳枬ãããæŽã«è¡
液詊æãè¬ç©ã®æåã®æäžã«å ç«ã€ãŠåãã ãã
åæäžã®åŸã24æéå床åãã ããè¡å°æ¿MAO
â掻æ§ã®æž¬å®ããããç¿ã¯AFHBAãæå°ã®æª
圱é¿ããåããã«èããã40mgïŒKgã®åäžæäžã®
åŸ22æéã§ïŒå¹ã«ã¯äžç¢ãèªãããããæçœãªæ
ååã³æŽ»åã¯ãè¬ç©æäžã«ãã€ãŠåœ±é¿ãããªãã€
ããè¡å°æ¿MAOâ掻æ§ã¯è©Šéšããå šãŠã®æäž
ã«æŒããŠé»å®³ãããããã«èŠããã
é 525(330ã720)
ã€)
ã©ãã(ã¹ã éèå é 308(161ã454)
ã©ã°ããŠã¬
é 241(142ã340)
ã€)
LD50å€åã³95ïŒ ä¿¡é Œéçã¯ããŒã¯ãœã³
ïŒBerksonïŒã®æå°ã«ã€äºä¹æ³ã®èšå·è«çåŠé¢æ°
ãçšããŠèšç®ãããããŠæäžåŸ14æ¥å ã«çããæ»
亡ã«åºã¥ããŠããã  ç¿ ïŒ çµå£ AFHBAã®æ¥æ§æ¯æ§ã®å€åãç¿(5)äžã§åŸããïŒ
å¹ã®éããã¢ã«ã¬ã¹ã¢ã³ããŒïŒcynomolgus
monkeyïŒïŒMacaca fascicularisïŒããã®ç 究ã§
çšãããç¿ã¯AFHBAã®10ã160mgïŒKgã®ç¯å²ã®
å¢å ããåäžçµå£æäžããããŒããŒã·ãšã³çã«å
ããïŒéŒ»èæ¿ç®¡æ³ã«ãã溶液åã¯æžæ¿æ¶²ãšããŠæ
äžïŒãè¬ç©ã®åæäžã®åŸãåç©ãæªãèšåºçãªåŸ®
ååã³çç¶ã«ã€ããŠïŒãïŒæ¥é芳枬ãããæŽã«è¡
液詊æãè¬ç©ã®æåã®æäžã«å ç«ã€ãŠåãã ãã
åæäžã®åŸã24æéå床åãã ããè¡å°æ¿MAO
â掻æ§ã®æž¬å®ããããç¿ã¯AFHBAãæå°ã®æª
圱é¿ããåããã«èããã40mgïŒKgã®åäžæäžã®
åŸ22æéã§ïŒå¹ã«ã¯äžç¢ãèªãããããæçœãªæ
ååã³æŽ»åã¯ãè¬ç©æäžã«ãã€ãŠåœ±é¿ãããªãã€
ããè¡å°æ¿MAOâ掻æ§ã¯è©Šéšããå šãŠã®æäž
ã«æŒããŠé»å®³ãããããã«èŠããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ åŒ ãåŒäžR3ã¯æ°ŽçŽ åã¯äœçŽã¢ã«ã³ãã·ã§ãããã
ã®ååç©åã¯ãã®ç¡æ¯ã®è£œè¬äžèªããããå¡©ã ïŒ åŒ ãåŒäžR3ã¯æ°ŽçŽ åã¯äœçŽã¢ã«ã³ãã·ã§ãããã
ã®ååç©åã¯ãã®ç¡æ¯ã®è£œè¬äžèªããããå¡©ãšã
補è¬äžèªããããæ äœåã¯åžéå€ãšããæ··åç©å
ã¯ä»ã®åœ¢ã§äžç·ã«ãªã€ããã®ãšããŠå«ãã§ããã
æ鬱çæ²»ççšçµæç©ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26855381A | 1981-06-01 | 1981-06-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57209257A JPS57209257A (en) | 1982-12-22 |
| JPH03376B2 true JPH03376B2 (ja) | 1991-01-07 |
Family
ID=23023501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57092251A Granted JPS57209257A (en) | 1981-06-01 | 1982-06-01 | Antidepressant compound and method |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS57209257A (ja) |
| ZA (1) | ZA823634B (ja) |
-
1982
- 1982-05-25 ZA ZA823634A patent/ZA823634B/xx unknown
- 1982-06-01 JP JP57092251A patent/JPS57209257A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| ZA823634B (en) | 1983-03-30 |
| JPS57209257A (en) | 1982-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5525631A (en) | Compositions of the ethyl ester of L-DOPA | |
| US5607969A (en) | L-DOPA ethyl ester to treat Parkinson's disease | |
| HUP0401097A2 (hu) | Karbociklusos hidrazinovegyÃŒletek, mint a réztartalmú aminoxidázok inhibitorai, eljárás az elÅállÃtásukra és ezeket tartalmazó gyógyszerkészÃtmények | |
| CH642618A5 (fr) | Phenethanolamines et compositions pharmaceutiques en contenant. | |
| US4421767A (en) | Compounds and methods for treating depression | |
| FR2530468A1 (fr) | Composition analgesique et anti-inflammatoire contenant de l'ibuprofen | |
| US4699928A (en) | Fluoroallylamine derivatives | |
| FI84057B (fi) | Foerfarande foer framstaellning av terapeutiskt aktiva fluorallylaminderivat. | |
| JPH0138087B2 (ja) | ||
| FR2896159A1 (fr) | Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline. | |
| US4413012A (en) | Method for treating depression | |
| US4346110A (en) | Method for treating depression | |
| EP0426562B1 (fr) | Dérivés de 1-(4-aminophényl)-2-pipéridinopropanone, procédé de préparation et utilisation en thérapeutique | |
| JPH03376B2 (ja) | ||
| FR2610932A1 (fr) | Nouvel acide piperazinecarboxylique, sa preparation et son utilisation comme medicament | |
| CA1190242A (en) | 2-amino-3-hydroxyphenyl-3-butenoic acid derivatives | |
| BE1003959A5 (fr) | Agent therapeutique pour le traitement de troubles associes a l'ischemie cerebrale. | |
| US4822812A (en) | β-(Fluoromethylene)-5-hydroxytryptophan and derivatives and their use as prodrugs for MAO inhibition | |
| FR2787328A1 (fr) | Utilisation d'un antagoniste des recepteurs 5ht2a pour la preparation de medicaments utiles dans le traitement des ronflements et du syndrome de haute resistance ou de resistance des voies aeriennes superieures | |
| US4879305A (en) | Use of β-(fluoromethylene)-5-hydroxytryptophan and derivatives as prodrugs and mao inhibition | |
| FR2888116A1 (fr) | Derives de thiazoles pour traiter les dyskinesies | |
| JPS5879919A (ja) | æççãé®çã解ç±å€ | |
| FR2744121A1 (fr) | Nouveaux derives de 2-chloro-3-arylamino-1-4-naphtoquinone, leur procede de preparation et leur utilisation comme agent pour inhiber l'agregation plaquettaire | |
| HK1012577B (en) | Composition of l-dopa esters |